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SUMMARY
125Binding sites of high affinity and low capacity for 1-angiotensm
II have been characterised in a cell membrane fraction derived from
mesenteric arterial arcades of the rat, resistance-type vessels which are
representative of the vascular target organs for angiotensin II.
Degradation of tracer angiotensin II and heterogeneity of binding sites
were accounted for by use of nonlinear regression methods for the analysis
125of radioligand binding data. Binding constants for 1-angiotensm II
obtained by different experimental approaches were in good agreement and
gave a dissociation equilibrium constant of 0.013-0.098nM (95% confidence
interval). Affinities for a number of angiotensin-related peptides derived
from competitive binding curves paralleled the pressor activities of these
125peptides with the order I-angiotensin II = angiotensin II > angiotensin
III > C-terminal hexapeptide > C-terminal pentapeptide »  angiotensin I = 
bradykinin. The iodinated peptide was found to retain full pressor 
activity in bioassay experiments. These binding sites therefore exhibit 
properties of a physiological receptor for angiotensin II.
The mechanism by which alteration of sodium balance brings about 
changes in pressor sensitivity to angiotensin II has been investigated by 
radioligand receptor assay. Sodium depletion (low salt diet + diuretic) 
caused a rapid increase in plasma angiotensin II concentration and a 
corresponding fall in receptor density from 102 ± 4 fmol/mg membrane 
protein (control) to 44 ± 5 fmol/mg protein at 12 days. Sodium loading and 
inhibition of angiotensin converting enzyme with captopril were equally 
effective in suppressing plasma angiotensin II concentration, but only in 
the captopril treated animals was an increase in receptor density observed 
(118 ± 6 fmol/mg protein at 12 days). Sodium loading caused a slow fall in
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receptor density, not significant at 5 days, to 77 ± 4 fmol/mg protein at 
12 days. This indicates that plasma angiotensin II concentration is not 
the sole determinant of vascular receptor status.
The results described above were obtained under standard assay
conditions with a Tris buffer containing 4.8mM Ca++. Using tissue from
normal animals, the apparent receptor density was found to vary with the
assay incubation medium calcium concentration over the range 0-10mM.
Receptor densities of 50 ± 4, 102 ± 4 and 156 ± 5 fmol/mg membrane protein
were obtained in low- (OmM), normal- (4.8mM) and high- (25mM) [Ca++] assay
respectively. After 2 days of sodium loading, sodium depletion and
converting enzyme blockade, the receptor densities determined in high- and
low-[Ca++] assays did not differ significantly from those of control
animals. Thus the altered receptor densities seen in normal-[Ca++] assay
++were due to shifts in the [Ca ]-receptor density relationship without 
apparent change in the total number of receptors. Similar results were 
obtained for the 12 day sodium loading and converting enzyme blockade 
experiments. In contrast, after 12 days of sodium depletion there was no 
difference in receptor density between normal- and high-[Ca++] assays (49 
± 7 fmol/mg) and the value obtained in low-[Ca++] assay was significantly 
below that for all the other groups.
These findings indicate two stages in the regulation of the vascular 
angiotensin receptor; an initial masking or inactivation of binding sites 
through a mechanism which is reversed by calcium, and (with elevation of 
plasma angiotensin II concentration) a subsequent loss of receptors. The 
factor responsible for the differing effects of converting enzyme blockade 
and sodium loading on receptor status appears to modulate this receptor 
masking/inactivating process. A mechanism by which this process operates 
is proposed.
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CHAPTER 1 
INTRODOCTiasr
1.1 The renin-angiotensin system
The renin-angiotensin system is illustrated diagramatically in 
Figure 1.1 and is described briefly below. A detailed account may be found 
in the reviews by Peach (1977) and Leckie & Semple (1983).
(a) Renin
The aspartate proteinase renin is synthesised and stored in the 
juxtaglomerular cells of the renal afferent arteriole, and is secreted 
into the bloodstream in response to a variety of stimulii. The enzyme is 
highly substrate specific, cleaving one leucyl-leucine or leucyl-valine 
peptide bond within a defined octapeptide sequence, and acts on its in 
vivo substrate (angiotensinogen, an alpl^ globulin of hepatic origin) 
to produce the decapeptide angiotensin I. The rate of renin release is 
controlled neurogenically through the extensive sympathetic innervation of 
the juxtaglomerular apparatus, by stretch receptors in the wall of the 
afferent arteriole, and by the macula densa, specialised cells in the 
thick ascending limb of Henle's loop. Renin release is also influenced by 
humoral factors, including plasma angiotensin II which acts in a negative 
feedback manner. Control of renin release has been reviewed by Davis & 
Freeman (1976) and Churchill (1985).
(b) Angiotensin I
Angiotensin I is the precursor of angiotensin II and has very 
little activity in pressor assays (Helmer, 1955) and on isolated smooth 
muscle (Bumpus et al, 1961; Campbell et al, 1977a). It also has little 
intrinsic activity in the adrenal cortex (Mendelsohn & Kachel, 1980) and 
central nervous system (Severs et al, 1973; Sirois & Gagnon, 1975; 
Chiaraviglio, 1976; Casner et al, 1976). Earlier suggestions that 
angiotensin I may act directly in certain evolutionally primitive
13
Figure
Angiotensinogen 
•----- •Renin
I
Angiotensin I 
•----- Angiotensin converting enzyme
Angiotensin II (^N-asp-arg-val-tyr-ile-his-pro-phe-CC^H)
Peptidase
enzymes
-4 VASCULAR SMOOTH MUSCLE
(peripheral vasoconstriction)
-•ADRENAL CORTEX
(mineralocorticoid secretion)
-• KIDNEY
(haemodynamic effects, altered tubular 
sodium transport ?)
-• HEART
(positive inotropic effect)
-•BRAIN
(haemodynamic/cardiovascular effects, 
thirst, vasopressin release)
-• SYMPATHETIC NERVOUS SYSTEM
(enhanced neurotransmission)
-•LIVER
(glycogen mobilisation)
-• PLATELETS
(increased sensitivity to aggregation)
Angiotensin IIII
Inactive metabolites
1.1 Schematic representation of the renin-angiotensin system, 
indicating the main actions of angiotensin II.
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structures within the brain, kidney and sympathetic nervous system (Peach, 
1977) have not been supported and at present it seems unlikely that 
angiotensin I has any important intrinsic activity.
(c) Angiotensin Converting Enzyme
Angiotensin converting enzyme is a zinc containing peptidyl- 
dipeptide hydrolase that splits the C-terminal histidyl-leucine (or 
serine-leucine in certain species) from angiotensin I, generating the 
active octapeptide angiotensin II. Converting enzyme also inactivates the 
vasodilator peptide bradykinin. The main site of conversion is the 
vascular endothelium, particularly in the pulmonary circulation. 
Converting enzyme is not rate-limiting in the formation of angiotensin II, 
and there is a close correlation between plasma renin and angiotensin II 
concentrations (Morton et al, 1976). A number of potent inhibitors of 
converting enzyme are known, originally peptides from the venom of 
Bothrops jararaca and subsequently synthetic agents such as captopril. 
These have been used extensively in studies on the renin-angiotensin 
system, and the orally-active inhibitors have found considerable clinical 
application in the treatment of various forms of hypertension. Angiotensin 
converting enzyme has been reviewed by Oparil (1977) and Cushman et al
(1981).
(d) Angiotensin II
The actions of angiotensin II will be considered in greater detail 
in Sections 1.2-1.8 with the receptors in each target tissue, but are 
summarised here.
(1) Blood pressure. Angiotensin II raises blood pressure by a direct 
vasoconstrictor effect, acting on small muscular vessels mainly in the 
cutaneous, splanchnic (Bohr & Uchida, 1967; Krasney, 1968; Forsyth et al, 
1971) and renal (Hollenberg et al, 1972) vascular beds. It may also 
increase cardiac output through a positive inotropic effect (Freer et al,
15
1976; Ackerly et al, 1977b; Trachte & Lefer, 1979). Prolonged infusion of 
angiotensin II at a rate below the threshold for an immediate pressor 
response also increases blood pressure; the mechanism of this slow pressor 
effect is unknown, but may involve baroreceptor resetting or an 
interaction with the sympathetic nervous system (Ames et al, 1965; Bean et 
al, 1979; Brown et al, 1981).
(2) Brain. Circulating angiotensin II gains access to the hypothalamic 
areas of the brain where the blood-brain barrier is deficient (Van Houtten 
et al, 1980), and stimulates thirst (Epstein et al, 1970; Ramsay et al,
1979) and ADH release (Bonjour & Malvin, 1970; Sladek & Joynt, 1980). It 
also increases central sympathetic discharge and facilitates sympathetic 
neurotransmission (review, Westfall, 1977). The pressor response to both 
centrally administered and (in part) blood-borne angiotensin II is 
probably mediated by the sympathetic nervous system (Falcon et al, 1978). 
There is also evidence that a separate renin-angiotensin system exists 
within the brain (review, Reid, 1977; Phillips et al, 1979; Printz et al, 
1982).
(3) Kidney. Angiotensin II decreases renal blood flow and glomerular 
filtration rate but increases filtration fraction (Navar & Langford, 1974; 
Davalos et al, 1978), suggesting a predominant locus of action on the 
post-glomerular efferent arteriole. However, autoradiographic studies have 
shown radio-labelled angiotensin II to localise mainly in the glomeruli, 
probably in cells of the mesangium (Osborne et al, 1975), and isolated 
glomerular capillary tufts will contract in response to physiological 
concentrations of angiotensin II (Sraer et al, 1974). Angiotensin II also 
causes sodium retention by a direct action on the kidney (Malvin & Vander, 
1967; Lohmeier et al, 1980). This may be due to altered glomerular 
haemodynamics (Myers et al, 1975), but there is evidence for a direct 
effect on tubular sodium transport (Steven, 1974; Harris & Young, 1977).
16
<As noted previously, angiotensin II is a potent inhibitor of renin 
release. The intrarenal effects of angiotensin II have been reviewed by 
Levens et al (1981).
(4) Adrenal cortex. Angiotensin II is a potent stimulus to aldosterone 
secretion and is believed to be the main regulator of adrenocortical 
steroidogenesis following changes in sodium balance (reviews, Brown et al, 
1977, 1979; Fraser et al, 1979). It also stimulates glucocorticoid release 
from the zona fasciculata (Ames et al, 1965; Kaplan, 1965; Bravo et al, 
1975a), but this effect is secondary (possibly vestigial) to ACTH 
(Vallotton et al, 1981).
(5) Other tissues. In addition to its major effects described above 
relating to cardiovascular regulation and electrolyte homeostasis, 
angiotensin II stimulates glycogen mobilisation in liver (Keppens & 
DeWulf, 1976) and increases the sensitivity of platelets to aggregation by 
epinephrine, ADP and thrombin (Poplowski, 1970; Ding et al, 1985b). 
Intestinal and uterine smooth muscle will contract in response to high 
concentrations of angiotensin II (Meyer et al, 1970; Turker et al, 1971; 
Papadimitriou & Worcel, 1974), but it is doubtful if this action has any 
physiological relevance.
(e) Metabolism of angiotensin II
In most species, the concentration of angiotensin II in plasma is 
in the range 5-200pM (Boucher et al, 1977). The peptide has a half-life in 
the circulation of 15-60 seconds (Cain et al, 1970; Brooks et al, 1977), 
and is degraded largely by aminopeptidases (Peach, 1977). No specific 
degradative enzyme has yet been identified, but there is evidence for 
alteration in metabolism of angiotensin II with changes in sodium balance 
(Leary & Ledingham, 1970). Only the C-terminal heptapeptide (des asp1 
angiotensin II, angiotensin III) has significant biological activity. 
Angiotensin III may be formed directly from angiotensin II or by the
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formation of des asp"*" angiotensin I which is a substrate for the 
converting enzyme (Garcia del Rio et al, 1981). The plasma concentration 
of angiotensin III is low in relation to angiotensin II (Semple & Morton, 
1976; Semple et al, 1976,1978). Although it has been established that the 
heptapeptide has approximately 30% of the pressor activity of angiotensin 
II (Schwyzer, 1963; Carey et al, 1978), estimates of its steroidogenic 
potency have varied widely, and it has been suggested that angiotensin III 
is the prime stimulus to aldosterone production (Freeman et al, 1976; 
Campbell & Pettinger, 1976). However, it now appears that the angiotensin 
receptors in the zona glomerulosa are similar to those in vascular smooth 
muscle and respond primarily to angiotensin II (Mendelsohn & Kachel,
1980). Angiotensin III also suppresses renin release, but again is less 
potent than angiotensin II (Naftilan & Oparil, 1978).
(f) Structure-activity relationships
The structure-activity relationships for angiotensin II have been
reviewed by Khosla et al (1974) and Bumpus (1977). The C-terminal
4 6 8pentapeptide (especially the tyrosyl , histidyl and phenylalanine
residues) is essential for biological activity. The guanido group of
position 2 is also important, as is the carboxyl group of position 8;
deletion of the latter causes almost total loss of biological activity.
The low activity of angiotensin I may be due to the separation of the
C-terminal carboxyl group from the phenylalanine residue. Species
variation occurs at position 5; in man, horse, pig, rat and probably
rabbit and dog isoleucine is present at this position, while in ox, fowl
and sheep valine is found. Douglas et al (1979) have suggested that
isoleucine in position 5 is necessary in maintaining correspondance
between receptor affinity and steroidogenic potency in species where this
is the natural form of angiotensin II.
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Smeby et al (1962) have proposed that angiotensin II may form an 
alpha helix with both aromatic rings, the imidazole ring of histidine and 
the C-terminal carboxyl group on one side. A variety of possible 
conformations have been proposed subsequently (Printz et al, 1972; 
Marshall et al, 1974; Fermanjian et al, 1976; Fromageot et al, 1976) with 
some controversy concerning the use of organic solvents in these studies. 
It appears that angiotensin II has a cross B-pleat structure in polar 
organic solvents, but is helical or subhelical in mixed aqueous/organic 
solvents and has little or no tertiary structure in aqueous solution.
(g) Inhibitory analogues
Ihe phenyl group of position 8 is essential for normal agonist 
activity, and substitution of phenylalanine by alanine, threonine or 
isoleucine yields potent angiotensin II antagonists (Saltman et al, 1976; 
Bumpus, 1977). The combination of alanine in position 8 and sarcosine in 
position 1 (Fessler et al, 1972) resulted in the first pharmacologically 
useful antagonist, saralasin. The sarcosine'*" substitution increases the
half-life of the peptide in the circulation (Hall et al, 1974; Pettinger 
et al, 1975) but also increases the affinity of the peptide for the 
receptor (Saltman et al, 1975). Substitutions which introduce a net 
positive charge at the N-terminus enhance the potency of the analogue 
while those introducing a negative charge decrease potency (Rioux et al, 
1973; Khosla et al, 1974). However, the affinity of the sarcosine1
antagonists for the vascular (and probably other) receptors is low in 
comparison to angiotensin II, since extremely high concentrations of 
antagonist (relative to angiotensin II) are required to inhibit pressor 
response to angiotensin II (Pettinger et al, 1975).
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1.2 Vascular angiotensin receptors
(a) Vascular smooth muscle
Early studies on the vascular angiotensin II receptors used aorta 
from various species (Lin & Goodfriend, 1970; Lin et al, 1970; Baudouin et 
al, 1971; Baudouin et al, 1972; Devynck et al, 1973; LeMorvan & Palaic, 
1975; Devynck & Meyer, 1976). Consistent with the lack of physiological 
action of angiotensin in this tissue, the affinity of the binding sites 
for angiotensin II is low in relation to normal plasma concentrations of 
the hormone, with reported values of 10-50nM. In other respects 
however, these binding sites show properties expected of a physiological 
receptor; they are located on the plasma membrane and discriminate between 
angiotensin peptides in a manner generally paralleling the pharmacological 
activities of these peptides. Aortic muscle will contract in response to 
high concentrations of angiotensin II, with ED^ -q values for contraction in 
the same range as the values (Meyer et al, 1970; Papadimitriou & 
Worcel, 1974; Regoli et al, 1974), indicating that these receptors are 
functional if insufficiently sensitive to respond to physiological 
concentrations of the hormone. However, there are many differences between 
aorta and the muscular resistance vessels in which angiotensin II acts. 
Whereas the pressor response to angiotensin II in intact animals exhibits 
marked tachyphylaxis on repeated or continuous administration of the 
hormone (Stewart, 1974), aortic muscle from various species will respond 
persistently (Khairallah et al, 1966; Altura & Altura, 1970; Palaic & 
LeMorvan, 1971), suggesting that the aortic receptors are not subject to 
the same regulatory processes as those in resistance vessels. Other 
differences between aorta and resistance vessels have been discussed by 
Devynck & Meyer (1976).
Bohr & Uchida (1967) found small mesenteric arteries to be highly 
sensitive to angiotensin II and to be representative of resistance-type
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vessels from other vascular beds. These vessels also exhibit tachyphylaxis
to angiotensin II, both as isolated muscle strips and as a perfused
preparation (Collis & Alps, 1975). Recently, Gunther et al (1980a) have
125investigated binding of I-angiotensin II to a crude membrane fraction 
derived from mesenteric vessels of the rat. They observed a single class 
of saturable binding sites with a of InM and which displayed the 
specificity for angiotensin peptides expected of a physiological receptor. 
Using the methods of Gunther et al (1980a) to investigate the regulation 
of these receptors, Aguilera & Catt (1981) and Schiffrin et al (1983c) 
obtained values of affinity and concentration agreeing closely with those 
of Gunther et al (1980a). Paller-et al (1984) have reported a similar 
value for the affinity but a considerably higher concentration of binding 
sites (300 vs 80 fmol/mg membrane protein) in this tissue.
(b) Non-vascular Smooth Muscle
Uterine muscle has frequently been used as a model for vascular 
smooth muscle (Lin et al, 1970; Meyer et al, 1974; Papadimitriou & Worcel, 
1974; Chevillotte et al, 1975; Rouzaire-Dubois et al, 1975; Devynck et al, 
1976; Moore et al, 1976; Devynck et al, 1979). The angiotensin II binding 
sites in this tissue resemble those described in aorta, with reported 
values and ED q^ values for contraction in the range 4-20nM. Only one study 
has directly compared angiotensin II binding in membrane fractions from 
rat uterus and mesenteric artery; Paller et al (1984) observed a four-fold 
lower affinity (K^  of 3.8 vs 0.9nM) in the former tissue. The similarities 
between uterine and vascular muscle have been discussed by Douglas & Brown
(1982) and Paller et al (1984). In addition to apparent regulation by 
plasma angiotensin II concentration, the density of angiotensin binding 
sites in the myometrium is markedly influenced by the changing oestrogen 
and progesterone levels during the ovarian cycle (Schirar et al, 1980a,b). 
Despite this, Paller et al (1984) observed qualitatively similar changes
21
in angiotensin II binding in uterine and mesenteric artery preparations in 
response to potassium depletion. In contrast, Aguilera & Catt (1981) found 
both the characteristics and regulation of angiotensin II binding sites to 
be identical in rat mesenteric artery and urinary bladder smooth muscle.
(c) Biochemical Characteristics of the Vascular Receptors
Most studies to date have concentrated on measurements of binding 
constants for angiotensin II and its analogues and changes in the binding 
constants under various physiological conditions, and relatively little is 
known about the receptors at the biochemical level. In aorta, binding of 
angiotensin II is markedly reduced by proteolysis, neuraminidase 
treatment and sulphydryl reducing agents, and is also inhibited by ATP and 
GTP, divalent cations, and to a small extent by potassium. Sodium has no 
effect in this tissue (Devynck & Meyer, 1976). In the rat mesenteric 
artery preparation, trypsin treatment and sulphydryl reagents are also 
inhibitory, but divalent cations (Ca++, Mg++, Mn++) markedly enhance 
binding of angiotensin II (Gunther et al, 1980a). Fleisch et al (1973) 
have reported N-ethyl maleimide and dithiothreitol to specifically block 
angiotensin II induced contractions in aortic muscle. Magnesium and 
manganese also inhibit muscle response to angiotensin II in vitro (Bohr, 
1974); this has been ascribed to competition for calcium binding sites. 
Sodium and divalent cations have been reported to increase binding of 
angiotensin II in rat mesenteric artery membranes through an increase in 
receptor affinity which is antagonised by GTP, while lithium and (to a 
much lesser extent) potassium were inhibitory (Wright et al, 1982). These 
authors have proposed the existence of a cation binding site closely 
related to the receptor.
Attempts to isolate the receptor have been hindered by its low 
affinity in detergent solubilised preparations (Devynck et al, 1974; 
Forget & Heisler, 1979). Solubilisation of the rabbit aortic receptor with
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sodium deoxycholate has been described (Devynck et al, 1974) but with 
altered peptide specificity and 10-fold lower binding capacity than in 
intact membranes. Capponi & Catt (1980) have used photoaffinity labelling 
to compare the physicochemical characteristics of dog adrenocortical and 
uterine angiotensin receptors; the results for both tissues were identical 
and showed the receptor to be a dimeric protein with similarly sized 
subunits of Mr 68000.
(d) Regulation of the vascular receptors
It has been recognised that pressor responsiveness to exogenously 
administered angiotensin II is altered in a variety of physiological and 
pathological conditions (Bartter et al, 1962; Chesley et al, 1963; Laragh 
et al, 1963; Kuchel et al, 1964; Healey et al, 1964; Kaplan & Silah, 
1964a,b; Reid & Laragh, 1965; Leary & Ledingham, 1970; Strouder & Walthen, 
1972; Hollenberg et al, 1972; Swales et al, 1975; Finchman et al, 1976). 
Changes in sodium balance have a profound effect on the renin-angiotensin 
system and have been extensively studied. In most circumstances, there is 
an inverse relationship between pressor sensitivity to the hormone and 
endogenous plasma levels of angiotensin II (or renin). Analogous changes 
in vascular sensitivity to angiotensin II have been demonstrated with 
perfused tissues (Strewler et al, 1972; Collis & Alps, 1975) and isolated 
aortic muscle (Strewler et al, 1972: Sybertz & Peach, 1980) taken from 
animals after activation of the renin-angiotensin system. Variation in 
angiotensin II vascular responsiveness is not associated with any change 
in sensitivity to norepinephrine (Thurston & Laragh, 1975; Oliver & 
Cannon, 1978) and is not mediated by bradykinin or prostaglandins (Oliver 
& Cannon, 1978). Changes in plasma sodium or potassium concentration 
within their respective physiological ranges also have no direct effect on 
angiotensin II responsiveness (Cowley & Lohmeier, 1978). It has been 
suggested that plasma angiotensin II concentration is the main determinant
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of sensitivity to angiotensin II (Thurston & Laragh, 1975; Devynck & 
Meyer, 1976; Oliver & Cannon, 1978; Cowley & Lohmeier, 1978; Dawson-Hughes 
et al, 1981). Other studies have shown that converting enzyme inhibition 
blocks the change in angiotensin II vascular sensitivity associated with 
dietary sodium deprivation but not that with sodium loading or nephrectomy 
(Thurston & Laragh, 1975; Oliver & Cannon, 1978).
It has been proposed that changes in angiotensin receptor affinity 
(Brunner et al, 1972) or that "prior occupancy" of the receptors by 
endogenous hormone (Davis et al, 1962; Thurston & Laragh, 1975; Oliver & 
Cannon ,1978) could account for the variation in pressor sensitivity to 
angiotensin II. However, radioligand binding studies have shown the 
concentration, but not the affinity, of angiotensin II binding sites to 
vary in aortic (Williams et al, 1976) and uterine (Chevillotte et al, 
1975; Devynck et al, 1976; Hauger et al, 1977; Devynck et al, 1979) muscle 
following alteration of plasma angiotensin II concentration.
These findings have been confirmed in the rat mesenteric artery 
preparation. Gunther et al (1980b) observed a decrease in the number of 
angiotensin receptors in this tissue in response to dietary sodium 
restriction that was reversed by administration of a converting enzyme 
inhibitor, and Aguilera & Catt (1981) demonstrated an inverse relationship 
between plasma angiotensin II concentration and receptor number. It would 
therefore appear that, as for many other hormones (reviews, Baxter & 
Funder, 1979; Catt et al, 1979), angiotensin receptor concentration is 
regulated by the prevailing plasma concentration of the hormone.
Changes in dietary potassium intake also influence the renin- 
angiotensin system; high potassium intake is associated with an enhanced 
pressor response to angiotensin II (Hollenberg et al, 1975; Douglas & 
Litowitz, 1978) while low potassium intake diminishes sensitivity (Linas & 
Dickman, 1982; Paller et al, 1984). Since plasma renin and angiotensin
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concentrations are inversely related to potassium intake (Brunner et al, 
1970; Sealey et al, 1970), these changes in responsiveness to the hormone 
might be ascribed to the same regulatory processes active during 
alteration of sodium balance. However, there is evidence that sodium and 
potassium depletion blunt vascular sensitivity to angiotensin II by 
independent mechanisms (Adamick et al, 1981). Also, Douglas (1979) found 
potassium loading to increase the affinity and decrease the concentration 
of angiotensin II binding sites in rat uterus, while Paller et al (1984) 
observed a decreased affinity and increased receptor concentration in 
response to potassium deficiency in rat uterus and mesenteric artery. 
Changes in affinity have not been reported in any muscle tissue in 
response to alteration of sodium balance, but Douglas & Brown (1982) found 
a substantial increase in affinity of uterine angiotensin II receptors 
following prolonged low-dose infusion of the hormone.
Schiffrin et al (1983c) have proposed that mineralocorticoids 
regulate the vascular angiotensin receptors; they found the binding 
properties of the mesenteric artery angiotensin receptors in two-kidney 
one-clip Goldblatt hypertensive rats to be identical to those of control 
animals despite considerably higher plasma renin activities in the 
hypertensive animals, although the capacity to down-regulate the vascular 
receptors in response to sodium depletion was preserved. Plasma 
aldosterone concentration was markedly elevated in the hypertensive 
animals. McGregor & Smirk (1968), Finch & Haeusler (1974) and Collis & 
Alps (1975) have reported a normal or increased responsiveness of the rat 
mesenteric vasculature to angiotensin II in renin-dependent renal 
hypertension, and Morton & Wallace (1983) have shown no change in net 
vascular responsiveness to the hormone in this model, although angiotensin 
II does cause the hypertension through a chronic mechanism (Wallace & 
Morton, 1984). A normal or enhanced response in human renovascular
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hypertension has been described by Brown et al (1976). Schiffrin et al 
(1983c) also observed a higher receptor density in DOC-salt hypertensive 
animals than salt-loaded controls although plasma renin concentration was 
similarly suppressed in both groups. The authors concluded that 
angiotensin II given acutely induces down-regulation of its vascular 
receptors, but that chronic elevation of plasma aldosterone concentration 
(such as occurs in the two-kidney one-clip renovascular model) or 
administration of a mineralocorticoid will up-regulate the receptors, 
possibly countering the effect of an elevated plasma angiotensin II 
concentration. While low pressor dose infusions of angiotensin II decrease 
the number of vascular receptors (Aguilera & Catt, 1981; Schiffrin et al, 
1983b), high pressor doses leave the receptor density normal or increased 
(Schiffrin et al, 1983b). Aldosterone infusion has been reported to 
up-regulate the vascular (Schiffrin et al, 1983a) and uterine (Brown & 
Douglas, 1982) receptors, and Schiffrin et al (1983a) have demonstrated a 
comparable effect in vitro with cultured vascular smooth muscle cells.
(e) Angiotensin tachyphylaxis
Repeated or continuous administration of angiotensin II results in 
specific desensitisation (tachyphylaxis) to the hormone, both in pressor 
assays in vivo and muscle contractile assays in vitro (Bohr, 1974; 
Stewart, 1974). The relationship between tachyphylaxis and receptor 
regulation is at present unclear. As in vascular muscle, the positive 
charges of the arginy^ guanido group and the N-terminal amino group are 
essential for full angiotensin II activity in guinea pig ileum and rat 
uterine muscle (Paiva & Paiva, 1960), and for the manifestation of 
angiotensin II tachyphylaxis (Paiva et al, 1974; Paiva & Paiva, 1975; 
Miasiro et al, 1983); angiotensin III does not induce tachyphylaxis. Freer 
& Stewart (1972) and Paiva et al (1977) found that angiotensin 
tachyphylaxis was accentuated in these tissues when the calcium
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concentration of the incubation medium was reduced, and Paiva et al (1977) 
have proposed that tachyphylaxis results from tight binding of angiotensin 
II in association with superficial calcium binding sites, and that 
recovery from tachyphylaxis involves displacement of the hormone by 
calcium. Rabbit aorta becomes tachyphylactic to sar^  angiotensin II but 
not to angiotensin II (Moore & Khairallah, 1976) and sar^ angiotensin II 
induced contractions in this tissue are markedly inhibited by slow calcium 
channel antagonists (verapamil and SKF-525A) and calcium-free media, while 
responses to angiotensin III are relatively unaffected; responses to 
angiotensin II are affected to an intermediate extent (Ackerly et al, 
1977a). Freer (1975) found that tissues which exhibit tachyphylaxis to 
angiotensin II show a marked reduction in response to the peptide in 
calcium-free media.
These findings indicate that tachyphylaxis is a function of the
N-terminus of the octapeptide, and that calcium can antagonise the
tachyphylactic mechanism. Acker ly et al (1977a) have inferred from the
differing effects of Ca++-free media on responses to angiotensins II & III
that these peptides act via different mechanisms. However, in muscle and
other tissues, direct binding studies have not provided any evidence for
separate receptors for these peptides. The observations of Freer (1975)
and Ackerly et al (1977a) are more consistent with loss of Ca++-antagonism
++of tachyphylaxis in Ca -free media, which will only affect peptides which 
induce tachyphylaxis. The effect of calcium channel blocking drugs implies 
that Ca++ acts at an intracellular site. It is also apparent that 
tachyphylaxis occurs to a differing extent in different muscle tissues; 
this also applies to vascular smooth muscle from different vascular beds 
(Bohr & Uchida, 1967). Since it seems unlikely that a different
angiotensin receptor subtype is present in each tissue, tachyphylaxis may 
be dependent on a receptor-related factor, the activity of which varies
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from tissue to tissue.
1.3 Adrenocortical angiotensin receptors
Angiotensin II is a potent stimulus to aldosterone production in 
many species (Davis, 1961; Laragh et al, 1961; Fraser et al, 1965; Ganong 
et al, 1967; Coleman et al, 1974) and is believed to be the prime 
regulator of steroidogenesis during sodium restriction (reviews, Brown et 
al, 1977, 1979). High affinity angiotensin II binding sites with values 
in the range 0.1-1 nM have been characterised in bovine (Glossman et al, 
1974c), rat (Glossman et al, 1974c; Douglas et al, 1978a) and canine 
(Douglas et al, 1976) zona glomerulosa cells, and angiotensin II shown to 
stimulate aldosterone production in these cells in vitro at physiological 
concentrations (Fredlund et al, 1975; Bing & Schulster, 1977; Douglas et 
al, 1978a).
(a) Biochemical characteristics of the adrenocortical receptor
As in vascular smooth muscle, sodium increases binding of
angiotensin II in this tissue but to a much greater extent. The effect of 
sodium appears to be antagonised by guanine nucleotides, and lithium is 
inhibitory. However, divalent cations have little effect on angiotensin II 
binding in adrenocortical membranes (Glossman et al, 1974a,b; Douglas et 
al, 1978a).
As previously described for the vascular receptors, attempts to
isolate the angiotensin receptor from adrenal cortex have been hindered by 
the extremely low affinity of the receptors following detergent 
solubilisation (Chang & Lotti, 1981). Photoaffinity labelling experiments 
have shown the adrenocortical receptor to be a dimeric protein with
similarly sized subunits of Mr 68000 (Capponi & Catt, 1980).
There has been some debate regarding the role of angiotensin III 
in this tissue. A number of pharmacological studies have indicated that 
the heptapeptide is a more potent steroidogenic agent (Bravo et al, 1975b,
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1976a; Peach et al, 1974, 1976) and that it acts through receptors 
selective for this peptide (Bravo et al, 1976b; Devynck et al, 1977). 
Other studies have shown angiotensin II to be more potent in this tissue 
(Campbell et al, 1977b; McCaa, 1978; Carey et al, 1978). However, it is 
now established that the adrenal and smooth muscle receptors are similar 
in that angiotensin III acts through the same receptor as the octapeptide 
but with lower affinity (Douglas et al, 1978b; Capponi & Catt, 1979; 
Aguilera et al, 1979; Douglas et al, 1980,1981).
(b) Regulation of the adrenocortical receptors
In contrast to the changes occuring in vascular tissues, sodium 
loading is associated with a blunted steroidogenic response to angiotensin 
II, while sodium depletion enhances sensitivity of the adrenal cortex 
(Ganong & Borzyczka, 1967; Kinson & Singer, 1968; Oelkers et al, 1974; 
Dawson-Hughes et al, 1981). Aguilera et al (1978,1980b) have demonstrated 
an initial change in affinity of the angiotensin receptors (at 36 hours) 
and a later change in receptor density (at 4 days) with normalisation of 
affinity following alteration of dietary sodium intake. These changes in 
binding properties were correlated with changes in responsiveness of 
glomerulosa cells in vitro. Douglas & Catt (1976) have also found an 
increase in glomerulosa cell angiotensin receptor density following 
prolonged sodium restriction. The effect of sodium depletion can be 
blocked by converting enzyme inhibition (Aguilera & Catt, 1978; Williams 
et al, 1978a; Aguilera et al, 1980b) and fully (Hauger et al, 1978; 
Aguilera et al, 1980a,b) or partly (Bojensen, 1966; Oelkers et al, 1975) 
reproduced by angiotensin II infusion; the discrepancy may arise through 
the dose of angiotensin II used, since high infusion rates diminish 
receptor density (Aguilera et al, 1980b). Also, changes in serum [K+] may 
be involved (see below), since serum [K+] may increase with sodium 
depletion but not with angiotensin II infusion (Boyd et al, 1971).
29
Dietary potassium loading is associated with elevated plasma 
potassium and aldosterone levels (Bojensen, 1966; Brunner et al, 1970; 
Douglas et al, 1978d), enhanced pressor and steroidogenic responses to 
angiotensin II (Hollenberg et al, 1975; Douglas & Litowitz, 1978; Douglas 
et al, 1978c) and hypertrophy of the zone glomerulosa (Deane et al, 1948; 
Douglas & Catt, 1976). The rise in serum [K+] presents a direct stimulus 
to steroid secretion (Funder et al, 1969; Haning et al, 1970) and also 
augments responsiveness to angiotensin II in vivo (Dluhy et al, 1972; 
McCaa et al, 1975; Douglas & Catt, 1976) and in vitro (Haning et al, 
1970). Douglas (1979) observed a decreased sensitivity but increased 
maximal steroidogenic response to angiotensin II in response to short-term 
potassium loading in the rat, and a corresponding decrease in affinity but 
increase in number of glomerulosa angiotensin receptors. Converting enzyme 
inhibition partly blocked the change in affinity, while angiotensin II 
infusion further increased the receptor density (Douglas, 1980). In rats 
maintained on a low potassium diet, plasma angiotensin II concentration 
was elevated 5-fold while glomerulosa cell receptor density fell (Douglas 
& Catt, 1976): a comparable increase in circulating angiotensin II 
concentration through infusion would be expected to increase receptor 
number (Hauger et al, 1978; Aguilera et al, 1980b).
Prolonged low-dose infusion of angiotensin II in dogs enhances 
pressor response to the hormone and blunts steroidogenic response (Bean et 
al, 1979). In rats, a similar protocol caused a decrease in affinity and 
increase in number of the zone glomerulosa angiotensin receptors (Douglas 
& Brown, 1982). Suppression of plasma angiotensin II concentration by 
aldosterone infusion produced a slight increase in affinity and a decrease 
in receptor density: when the hypokalemia associated with aldosterone 
infusion was prevented (high potassium diet), the decrease in receptor 
density was largely attenuated (Douglas & Brown, 1982).
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These findings indicate that potassium can act independently of 
and synergistically with angiotensin II in the zone glomerulosa: potassium 
appears to be a more important regulator in that it can override the 
effects of angiotensin II. It is possible that the changes in pressor 
sensitivity to angiotensin II seen during alteration of dietary potassium 
intake are mediated through changes in plasma aldosterone concentration, 
if aldosterone exerts a regulatory effect on the vascular receptors as 
suggested by Schiffrin et al (1983c). Together with the changes in 
receptor affinity (in general, directionally similar to the changes in 
plasma angiotensin II concentration) and the differing effects of low- and 
high-dose angiotensin II infusion, these observations suggest that a 
number of processes are active in regulating adrenocortical steroido­
genesis and sensitivity to angiotensin II.
1.4 Renal angiotensin receptors
Alteration of sodium balance is associated with changes in 
glomerular filtration rate (GFR) (Beaufils et al, 1976; Skorecki et al, 
1983) and angiotensin II has been shown to influence glomerular capillary 
ultrafiltration coefficient (Myers et al, 1975; Blantz et al, 1976; 
Lohmeier et al, 1977). Specific binding of angiotensin II to isolated rat 
glomerular capillary tufts has been demonstrated and angiotensin II shown 
to stimulate contraction of the capillary tufts with an ED^ of 50pM, 
similar to the value of the binding sites (Sraer et al, 1974; Beaufils 
et al, 1976). Low affinity binding sites were also observed but not 
characterised. Ballerman et al (1984) and Bellucci & Wilkes (1984) report 
a single class of binding sites (K^  values of 0.35nM and 4nM respectively) 
in rat glomeruli, while Chansel et al (1982) have described cooperativity 
in angiotensin II binding to human glomerular capillary tufts (K^  in the
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range 0.1-2nM). Autoradiographic studies have shown H-angiotensin II to 
localise predominantly over the cytoplasm of renal mesangial cells
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(Osborne et al, 1975); these cells are known to contain contractile 
elements (Becker, 1972; Ausiello et al, 1980) and to contract in response 
to angiotensin II (Fiodart et al, 1980). The latter authors report a 
single class of angiotensin II binding sites on mesangial cells with a 
of 2nM, agreeing with their value for the ED^q for contraction. The 
changes in GFR associated with alteration of sodium balance have been 
correlated with changes in receptor density and affinity (Beaufils et al, 
1976) or in receptor density only (Ballerman et al (1984); Bellucci & 
Wilkes (1984).
Low doses of angiotensin II promote sodium and water retention, 
while large doses (pressor) are natriuretic (Ploth & Gabriel, 1979). A 
number of studies have suggested that angiotensin II may directly 
stimulate sodium reabsorption within the kidney (Johnson & Malvin, 1977; 
Harris & Young, 1977; Freedlender & Goodfriend, 1977; Levens et al, 1981), 
and angiotensin II has been shown to alter sodium fluxes in renal proximal 
tubular cells (Steven, 1974; Freedlender et al, 1979,1980) apparently by 
activating a oubain-insensitive sodium pump (Munday et al, 1971). 
Specific, high affinity (K^ =6nM) angiotensin binding sites have been 
identified on both the luminal (brush border) and contraluminal 
(basolateral) tubule membranes (Brown & Douglas, 1982). In this tissue, 
sodium increased the affinity of receptors while divalent cations 
increased the receptor density; these effects were additive.
As previously noted, angiotensin II inhibits renin release; this 
effect is receptor mediated since it occurs in isolated, perfused kidneys 
and superfused kidney slices (Davis & Freeman, 1976), and in vivo at 
sub-pressor doses of angiotensin II (Bean et al, 1979). The receptors 
mediating this response show the same discrimination between angiotensin 
analogues as those in vascular muscle and adrenal cortex (Naftilan & 
Oparil, 1978).
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1.5 Central angiotensin receptors
There is considerable evidence that angiotensin exerts effects on 
both the central and sympathetic nervous systems. Blood-borne angiotensin 
gains access to the circumventricular organs of the rat brain (Van Houtten 
et al, 1980) and immunohistochemical methods have identified angiotensin­
like material in nerve terminals (Fuxe et al, 1976; Changaris et al, 
1978). It has also been proposed that a separate renin-angiotensin system 
exists within the brain, since all the components appear to be present in 
this tissue (Ganten et al, 1976; Reid, 1979; Printz et al, 1982).
Angiotensin II is known to stimulate thirst (Epstein et al, 1970; 
Ramsay et al, 1979) and vasopressin release (Bonjour & Malvin, 1970; 
Sladek & Joynt, 1980) and to facilitate autonomic neurotransmission at 
many levels in the central and peripheral nervous systems (reviews, Peach, 
1977; Westfall, 1977). The effect on autonomic transmission is largely due 
to enhancement of norepinephrine release, although angiotensin II has been 
shown to increase neuronal firing rate (Phillips et al, 1979) and 
catecholamine content (Sumners & Phillips, 1983). Intraventricular 
microinjection of angiotensin II causes a pressor response (Buckley & 
Jandhyala, 1977; Phillips, 1978) which is due in part to increased 
efferent sympathetic activity (Falcon et al, 1978).
Binding sites with equal affinity for angiotensins II & III (K^  
0.2nM) have been identified in rat brain (Bennett & Snyder, 1976, Mann et 
al, 1978,1981). Consistent with actions of angiotensin in the circum­
ventricular organs, the highest density of binding sites was seen in the 
thalamus, hypothalamus and midbrain. A similar distribution but slightly 
lower affinity (K^  0.9nM) has been reported by Sirrett et al, (1977). Mann 
et al (1978, 1981) were able to correlate the central pressor and 
dypsogenic activities of various angiotensin analogues with affinity for 
the receptor, and found a decrease in pressor response to centrally
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administered angiotensin II to coincide with a reduction in receptor 
density during dietary sodium restriction. In bovine cerebellar cortex, 
Bennett & Snyder (1980a,b) observed two classes of angiotensin binding 
sites (K^ 's 80 and 500pM). Alteration of the incubation medium sodium ion 
concentration (10-150mM) exerted a differential effect on binding of 
angiotensin II and sar'*' substituted octapeptide analogues in that it 
increased the affinity (25-fold) of the high affinity sites for the native 
peptide only. This effect was a function of both ionic size and ionic 
strength and was dependent on the N-terminal aspartate residue.
Although angiotensins II & III have equal affinity for the brain 
receptor, the heptapeptide has much less pressor activity when 
administered centrally. Angiotensin I has little pressor activity and a 
very low affinity for the receptor (Mann et al, 1978,1981). The central 
and sympathetic responses to angiotensin II are resistant to tachyphylaxis 
(Fukiyama et al, 1971; Sweet et al, 1971).
In spontaneously hypertensive rats, pressor responsiveness to 
centrally administered angiotensin II is enhanced (Hoffman et al, 1977), 
while intraventricular administration of saralasin causes a reduction in 
blood pressure (Schoelkens et al, 1976; Phillips et al, 1977; Mann et al, 
1978). Central administration of the angiotensin II antagonist also 
reduces blood pressure in renin-dependent renal hypertension (Schoelkens 
et al, 1976; Sweet et al, 1976; Mann et al, 1978) but not in normotensive 
rats (Phillips et al, 1977). Similar results were obtained by Suzuki et al
(1981), who also observed that similar effects were produced by captopril 
when administered by this route, and that in addition to changes in blood 
pressure, parallel changes in plasma renin activity occurred.
The density of angiotensin receptors in spontaneously hypertensive 
rat brain is greater than in Wistar-Kyoto control animals (Stamler et al, 
1980). Neuronal cells from the hypertensive rats (at 1 day, before the
34
hypertension is established) in culture also show a higher receptor 
density (Raizada et al, 1984). Sumners et al (1983) found an inverse 
relationship between neuronal catecholamine content and receptor affinity 
in cultures from normal animals; this relationship was lost in the 
cultured cells from the hypertensive rats (Raizada et al, 1984).
1.6 Cardiac angiotensin receptors
Angiotensin II exerts positive inotropic and chronotropic effects 
on the heart. While the chronotropic effect is mediated through the 
sympathetic nervous system (Nishith et al, 1962; Krasney et al, 1966), the 
inotropic effect can be demonstrated in vitro (Koch-Weser, 1964; Fowler & 
Holmes, 1964) and is unaffected by B-adrenergic blocking drugs (Dempsey et 
al, 1971; Blumberg et al, 1975). Several studies have indicated that
angiotensin II augments Ca++ influx during the action potential plateau 
(Beeler & Reuter, 1970; Bonnardeaux & Regoli, 1974; Shigenobu et al, 
1974), an effect which can be blocked by verapamil and Mn++ (Freer et al, 
1976) and angiotensin antagonists (Bonnardeaux & Regoli, 1974; Freer et 
al, 1976).
In bovine heart Mukherjee et al (1982) observed a single class of
angiotensin binding sites with a of 2nM but attempted no further
characterisation. In a detailed study by Wright et al (1983) using rabbit
125ventricular tissue, two classes of binding sites for I-angiotensin II
1 8(K^  values 2.4 and 9.6nM) were observed. The partial agonist sar ile 
angiotensin II appeared to interact only with the high affinity binding 
sites, and the density of high affinity sites was reduced by monovalent 
cations (Na+, K+, Li+, NH^ ) and increased by divalent cations (Ca++, Mg++) 
without alteration in affinity. The affinity of both classes of sites was 
reduced by guanine nucleotides (increase in dissociation rate constants), 
but in the presence of GTP, angiotensin II (luM) did not affect 
isoproterenol-stimulated adenylate cyclase activity. Baker et al (1984)
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have characterised a single class of binding sites for I-angiotensin II
in this tissue but did not exclude the possibility of a second class of
low-affinity sites. These authors also found divalent cations to enhance
binding and guanine nucleotides to be inhibitory.
1.7 Hepatic angiotensin receptors
In the liver, angiotensin II stimulates carbohydrate mobilisation
(Hems et al, 1978; Exton, 1980; Hems & Whitton, 1980) and synthesis of
renin substrate (Freeman & Rostorfer, 1972; Sernia & Reid, 1980) and
attenuates activation of adenylate cyclase (Jard et al, 1981; Crane et al,
1982; Cardenas-Tanus et al, 1982). The effects on carbohydrate metabolism
are mediated through a cAMP-independent Ca++-requiring pathway (Garrison
et al, 1979; Sexton, 1981) and angiotensin II and glucagon have been shown
to affect the phosphorylation states of partially overlapping sets of
cytoplasmic proteins in this tissue (Garrison, 1978; Garrison et al, 1979;
Garrison & Wagner, 1982). The attenuation of adenylate cyclase activity is 
++not Ca dependent (Jard et al, 1981; Cardenas-Tanus et al, 1982).
Lafontaine et al (1979) observed a single class of binding sites
in rat liver membranes with a of 0.1 nM, while Campanile et al (1982)
and Crane et al (1982) report two classes of binding sites with values
of 0.2 and 3 nM. Sodium and GTP interact with the high affinity binding
sites in a manner similar to that, described for the rat mesenteric artery
angiotensin receptor (Wright et al, 1982), and Campanile et al (1982) were
able to correlate the binding affinities of various angiotensin analogues
with their ability to activate glycogen phosphorylase. However, Sen et al
(1983) found only a single class of binding sites in intact and digitonin-
solubilised rabbit liver membranes (K^  values 0.5 and 10 nM respectively).
Using SDS-polyacrylamide gel electrophoresis they observed a single
125radiolabelled band after covalently linking I-angiotensin II to its 
binding site [Mr=68000, identical to the value obtained by Capponi & Catt
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(1980) for the dog uterine and adrenocortical receptor]. Like Campanile et 
al (1982) and Crane et al (1982), Gunther (1984) observed two classes of 
binding sites in rat liver membranes (K^  values 0.35 and 3 nM). The high 
affinity sites were inactivated by sulphydryl reducing agents, which also 
blocked angiotensin II stimulation of glycogen phosphorylase activity. 
This effect was specific for angiotensin II, and did not affect 
angiotensin II inhibition of adenylate cyclase. Sulphydryl reagents 
specifically inactivate the vascular angiotensin receptor (Gunther et al, 
1980a) and block vascular smooth muscle response to angiotensin II 
(Fleisch et al, 1973). The ED,-q 's for phosphorylase activation and 
inhibition of adenylate cyclase are 0.3-0.8 nM (Keppens & DeWulf, 1976; 
Hems et al, 1976) and 3 nM (Jard et al, 1981) respectively. Gunther (1984) 
was able to correlate the computed fractional occupancy of the high and 
low affinity receptors with the degree of phosphorylase activation and 
cyclase inhibition respectively, and has proposed that each effect is 
mediated by a distinct angiotensin receptor subtype.
Investigating the regulation of the angiotensin receptors in rat 
liver, Sernia et al (1985) observed a single class of angiotensin II 
binding sites with a of 0.3 nM. Binding was increased by divalent 
cations and abolished by dithiothreitol. Sodium loading caused a complex 
response similar to that seen in adrenal cortex. An initial fall in 
receptor density (at 1.5 days) was followed by an increase to a level 
above control (maximal at 9 days) and then a slow return towards the 
control value. Changes in affinity directionally opposite to the changes 
in receptor density were also observed. Angiotensin II infusion caused an 
increase in receptor density without any change in affinity.
1.8 Platelet angiotensin receptors
The sensitivity of platelets to aggregation by epinephrine and ADP 
is increased by angiotensin II (Poplowski, 1970; Ding et al, 1985b), and
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binding sites with the properties expected of a physiological receptor for 
angiotensin have been identified on human platelets. Moore & Williams
(1982) observed a single class of specific, saturable sites with a 
value of 240pM, and found the number of binding sites (approximately 10 
sites/cell) to vary inversely with (4 days) dietary sodium intake. No 
specific binding of angiotensin II to erythrocytes or mononuclear 
leukocytes could be demonstrated. Similar results for the affinity and 
concentration of binding sites have been reported by Ding et al (1984) and 
Mann et al (1985).
Investigating the regulation of the platelet receptors, Moore et 
al (1984) found rapid alteration of plasma angiotensin II concentration 
(by volume loading or depletion) to cause a directionally opposite change 
in binding capacity which was not significant at 4 hours and which reached 
a plateau at 24-48 hours. This time-course suggests that prior occupancy 
of the receptors does not account for the observed changes in binding 
capacity, and these authors have proposed that receptor regulation occurs 
at the level of the megakaryocyte with the observed changes in binding 
capacity reflecting the rapid turnover of platelets, or that regulation 
occurs by masking and unmasking of preformed receptors as has been 
proposed for the hepatic insulin receptor (Krupp & Lane, 1981). Ding et al 
(1985a) also observed an inverse relationship between plasma angiotensin 
II concentration and platelet receptor density during alteration of sodium 
balance but found no change in angiotensin binding with alteration of 
dietary potassium intake. These authors also observed no difference in 
platelet angiotensin II binding between normotensive human subjects and 
patients with essential hypertension.
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1.9 Post-receptor Events
Angiotensin II action has been associated with changes in the
electrical properties of smooth muscle (Keatinge, 1966; Ohashi, et al,
1967; Somlyo & Somlyo, 1970) and adrenocortical (Natke & Kabella, 1979)
cells, and with changes in transmembrane sodium flux (Friedman et al,
1959; Friedman & Allardice, 1962; Villamil et al, 1970). Extracellular
Ca++ is required for angiotensin action in adrenal cortex (Fakunding &
Catt, 1980), kidney (Vandongen & Peart, 1974; Fray & Park, 1979), liver
(Garrison et al, 1979; Sexton, 1981), heart (Bonnardeaux & Regoli, 1974;
Freer et al, 1976) and smooth muscle (see below). From an electro-
physiological study on uterine muscle, Hamon & Worcel (1979) concluded
that angiotensin II simultaneously increases membrane conductance to Na+
and K+. The changes in membrane conductance occured when the membrane
potential was held at its resting level, did not appear to involve Ca++
or Cl-, and were only slightly affected by ouabain. The sequence of events
proposed by these authors is; 1) an initial rapid depolarisation that
triggers the discharge of spikes; 2) simultaneous with the depolarisation,
and before any spike production, a tonic contraction starts; 3) coincident
with the spikes, phasic contractions are superimposed on the tonic
contraction; 4) once tachyphylaxis (or hormone washout) starts, relaxation
of the muscle follows the fading of the depolarisation. The tonic
contraction appeared to be independent of changes in transmembrane Ca++
flux (and only occured once in Ca++-free media), while the phasic
contractions were dependent on extracellular Ca++; in this tissue it has
been demonstrated that each spike is the result of a potential-dependent 
++Ca gating (Mironneau, 1974; Vassort, 1975). These results are consistent 
with previous reports of two stages in angiotensin action; an early stage 
which uses intracellular Ca++, and the late, chronic stage which is 
dependent on extracellular Ca++ (Deth & Van Breemen, 1974,1977). However,
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the role of changes in membrane potential is unclear, since angiotensin II 
is known to contract vascular smooth muscle in the presence of 
depolarising concentrations of potassium (Bohr, 1974). In the studies 
cited above in which membrane depolarisation in response to angiotensin 
II was observed, the use of high concentrations of the peptide may have 
produced artefactual results.
In more recent studies, the effects of angiotensin II on trans­
membrane Na+ and K+ flux has been shown to be the result of activation of 
the amiloride-sensitive Na+/H+ exchange carrier, with the rise in 
intracellular [Na+] stimulating the Na+/K+ ATPase and thereby attenuating 
the change in membrane potential induced by the sodium influx (Brock et 
al, 1982; Smith & Brock, 1983). This is consistent with effects of ouabain 
observed by Hamon & Worcel (1979).
Much has been learned recently about the role of phosphoinositide
turnover in hormone action. A number of hormones have been shown to
activate a membrane-bound phosphodiesterase (phospholipase C) that
hydrolyses the membrane lipid phosphatidylinositol 4,5-bisphosphate
(PtdIns(4,5)P2) producing inositol 1,4,5 trisphosphate (InsP^) and
diacylglycerol. InsP3 stimulates Ca++ release from the endoplasmic
reticulum (and may have other actions) while diacylglycerol acts in the
plane of the membrane to activate protein kinase C, which in turn may
activate the amiloride-sensitive Na+/H+ exchange carrier (for review, see
Berridge & Irvine, 1984). Angiotensin II has been shown to stimulate the
hydrolysis of PtdIns(4,5)P2 in liver (Kirk et al, 1981) and the synthesis
and hydrolysis of PtdIns(4,5)P2 in adrenal cortex (Farese et al, 1984) and
aortic smooth muscle cells in culture (Smith et al, 1984). In the latter
study, which was confined to the immediate effects of angiotensin II, Ca++
efflux from the cells was observed, consistent with mobilisation of intra- 
++cellular Ca . Angiotensin II has previously been shown to increase the
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++rate of efflux of Ca from an aortic muscle microsomal fraction, probably 
plasma membrane or endoplasmic reticulum (Baudouin et al, 1972). Removal 
of extracellular Ca++ did not influence the experimental observations of 
Smith et al (1984), and Ca++ influx was not stimulated. These results 
suggest that the initial phase of tissue response to angiotensin II is 
mediated by intracellular Ca++ mobilised through the action of InsP^ . The 
mechanism of the slow component of the response is as yet unknown. Smith 
et al (1984) have proposed that Ca++ influx is stimulated by the change in 
membrane potential; this may take the form of potential-dependent gating 
of Ca++ (although this apparently only occurs at high concentrations of 
the peptide) or modulation of Na+/Ca++ exchange carrier activity by the 
rise in intracellular [Na+], as proposed by Lang & Blaustein (1980). 
Alternatively, the initial increase in intracellular [Ca++] may directly 
stimulate Ca++ influx as discussed by Bolton (1979).
Cyclic GMP may also mediate tissue response to angiotensin II. 
Ewans et al (1976) found cGMP to mimic the effects of the hormone on 
cation transport in kidney slices, and angiotensin II administration has 
been reported to increase plasma concentrations of cGMP in humans (Roseman 
et al, 1976) and the cGMP content of rat aortic, heart and kidney tissues 
(Vesely, 1981).
Many hormone receptors are known to be coupled to their 
effector(s) through a guanine nucleotide-binding regulatory protein 
(review, Gilman, 1984). Little direct evidence is available in this 
respect for angiotensin II, although the inhibitory effect of GTP and GTP 
analogues on binding of angiotensin II in many tissues indicates the 
involvement of such a factor. Also, a number of other hormone receptors 
which act via the InsP^/diacylglycerol Ca++-mobilising pathway are 
believed to be coupled to phospholipase C via a GTP-binding protein 
(review, Berridge & Irvine, 1984).
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CHAPTER 2 
MATERIALS AND BIOCHEMICAL METHODS
2.1 Materials
(a) Biochemicals
All reagents were of the best grade available commercially. With 
the exception of those listed below, all were obtained from BDH Chemicals 
Ltd., Poole, Dorset, U.K.
Albumins [bovine, fraction V, (product number A-4503), and rabbit, 
crystalline], ATP, l-ethyl-3-(3-dimethyl-amino-propyl)-carbodiimide HC1, 
cyclic AMP, cyclic GMP, glucagon (crystalline), Gpp(NH)p, GTP, inosine 
5'-triphosphate, o-phenanthroline monohydrate, phenylmethanesulphonyl- 
fluoride, soybean trypsin inhibitor, Tos-Phe-C^Cl and neomycin sulphate 
were obtained from Sigma (London) Chemical Company Ltd., London, U.K.
Di-isopropyl phosphite was obtained from Koch-Light Laboratories 
Ltd., Coinbrook, Buckinghamshire, U.K.
DEAE-Sephadex A-25 and dextran T-70 were supplied by Pharmacia 
(Great Britain) Ltd., Hounslow, Middlesex, U.K.
Freund's Adjuvant was purchased from Gibco Laboratories Ltd., 
Paisley, Strathclyde, U.K.
Iodogen (1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril) was obtained 
from Pierce Biochemical Corp., Rockford, Illinois, U.S.A.
Human serum albumin was obtained from A.B. Kabi, Stockholm, Sweden. 
Norit SXI charcoal was supplied by Haller & Phillips Ltd., London,
U.K.
(b) Radiochemicals
Tyrosyl -^i- [ile^] angiotensin I and tyrosyl -^i- [ile^]
angiotensin II were obtained from New England Nuclear, Southampton, U.K.
125Carrier-free Na I was supplied by the Radioisotope Dispensary, 
Western Infirmary, Glasgow.
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(c) Pharmaceuticals
Trasylol was obtained from Bayer Pharmaceuticals Ltd., Haywards 
Heath, Sussex, U.K.
Frusemide B.P. (Lasix) was obtained from Hoechst (UK) Ltd., 
Pharmaceuticals Division, Middlesex, U.K.
Captopril was supplied courtesy of E.R. Squibb & Sons Inc., 
Princeton, New Jersey, U.S.A.
(d) Peptides
Angiotensin II C-terminal hexapeptide and C-terminal pentapeptide 
were obtained from Schwartz Bioresearch, Orangeburg, New York, U.S.A. All 
other angiotensin peptides, arginine vasopressin and bradykinin were 
purchased from Cambridge Biochemicals Ltd., Harston, Cambridgeshire, U.K. 
and Peninsula Laboratories (Europe) Ltd., Merseyside, U.K.
(e) Animals
Male Sprague-Dawley rats (body weight 325-350g) were purchased 
from Olac Ltd., Shaws Farm, Oxfordshire, U.K. and Charles River Ltd., 
Margate, Kent, U.K.
(f) Membrane filters
Membrane filters were obtained from Millipore (UK) Ltd., Harrow, 
Middlesex, U.K. and Whatman Ltd., Maidstone, U.K.
2.2 General methods
(a) Micropipetting
Solution volumes in the range 5ul to 5ml were transferred 
reproducibly using adjustable "Finnpipettes" [Jencons (Scientific) Ltd., 
Leighton Buzzard, Bedfordshire, U.K.]. Larger volumes were dispensed using 
standard laboratory volumetric glassware.
(b) Weighing
Milligram quantities were measured using a Mettler type M5SA 
balance (Gallenkamp & Co. Ltd., East Kilbride, Glasgow, U.K.). For larger
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quantities a Mettler type AE-160 balance was used.
(c) pH measurements
Measurements of pH were made using an Elcomatic Instruments Ltd., 
model 7065 digital pH meter and a standard combination electrode 
(Gallenkamp & Co. Ltd., East Kilbride, Glasgow, U.K.). This apparatus was 
regularly calibrated using solutions of pH 4.0, pH 7.0 and pH 9.0 prepared 
using buffer tablets (BDH Chemicals Ltd., Poole, Dorset, U.K.). The pH 
measurements were made at the temperature at which the buffers were to be 
used.
(d) Centrifugation
Accelerations of up to 2000g were obtained using a Damon DPR-6000 
centrifuge [Damon/IEC (U.K.) Ltd., Dunstable, Bedfordshire, U.K.]. 
Accelerations of up to 100,000g were obtained using a Beckman L2-65B 
centrifuge fitted with a titanium Ti-60 rotor (Beckman RIIC Ltd., 
Glenrothes, Fife, U.K.) or an MSE Superspeed-65 centrifuge fitted with an 
MFT 60.35 titanium rotor (MSE Ltd., Crawley, Sussex, U.K.). Centrifugation 
was performed at 2°C. For small samples, accelerations of 10,000g were 
obtained with an MSE "Microcentaur" benchtop centrifuge taking 1.5ml 
tubes.
(e) Preparation of buffers
All solutions were prepared in glass-distilled water. Buffers for 
receptor-binding experiments were filtered through a 0.2um filter using a 
Millipore "Sterifil" apparatus [Millipore (UK) Ltd., Middlesex, U.K.] to 
remove particulate matter and refrigerated until used.
(f) Measurement of protein concentration
Protein concentration was measured by a modification of the method 
of Lowry et al (1951). Stock solutions were prepared as follows; 2% (w/v) 
Na^O^ (anhydrous) in O.lM-NaOH, 2% (w/v) CuS0^.5H20 in water, 4% (w/v) 
sodium potassium tartrate tetrahydrate in water. These solutions were
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mixed in the proportions 40:1:1 by volume shortly before use, and 2.5ml of
the mixture added to a protein sample in 200ul of 50mM-Tris buffer. The
samples were vortexed and allowed to stand for 15 minutes with occasional
re-mixing. 250ul of Folin & Ciocalteau's phenol reagent diluted in water
(5:3 v/v) was then added, the mixture vortexed immediately and allowed to
stand for at least 60 minutes prior to determination of the absorbance at
700nm. Protein standards (20-200ug) were prepared using bovine serum
albumin (fraction V) dissolved in 50mM-Tris buffer. Normally, 4 protein
samples and 4 blanks of the appropriate buffer were taken for each
experiment.
(g) Measurement of radioactivity
Radioactivity was determined using an NE1612 gamma counter (>90%
efficiency) (Nuclear Enterprises Ltd., Sighthill, Edinburgh, U.K.). For
low activity samples, the machine was calibrated for background count
rates before use and the sample count rates automatically corrected.
2.3 Preparation of radioligands
(a) Angiotensins I & II 
125 5Tyrosyl I- [lie ] angiotensin II was obtained from New England
Nuclear as a lyophilised powder, and was dissolved in the appropriate Tris
buffer containing 1% (w/v) bovine albumin and stored at -20°C. Specific
activity and radiochemical purity were determined as described below and
were found to be within the manufacturers specifications of 2000Ci/mmol
and >98% respectively. For the routine receptor assay, or when high
125concentrations of I-angiotensin II (>10nM) were required, the specific
c
activity was reduced 4-5 fold by addition of unlabelled [lie ] angiotensin
II. Iodinated angiotensins I & II for radioimmunoassay of these peptides 
were also obtained from New England Nuclear and were dissolved to the 
approximate required concentration in the appropriate Tris buffer and 
stored at -20°C.
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(b) Iodination of angiotensin II antagonists
Angiotensin II antagonists were iodinated essentially as described 
by Fraker & Speck (1978). Iodogen (l,3,4,6-tetrachloro-3a,6a-diphenyl 
glycoluril) was dissolved in redistilled methylene chloride and 200ul 
(120ug Iodogen) placed in a 10mm diameter flat-bottomed glass tube and 
dried at 45°C. Carrier-free Na^^I (3mCi) in 20ul of O.lM-NaOH was 
neutralised with O.lM-hydrochloric acid and 200ul of O.lM-Tris HC1 (pH 
7.2)/0.154M-NaCl containing 2.5ug of peptide added. This mixture was 
transferred to the tube containing the Iodogen and the reaction allowed to 
proceed for 1 hour on ice. 200ul of O.lM-Tris HC1 (pH 7.2)/0.lM-sodium 
metabisulphite/O.2M-KI was then added and the mixture chromatographed on 
DEAE Sephadex A-25 (27 x 1.5cm) which had been equilibrated with O.lM-Tris 
HC1 (pH 8.0)/0.2% (w/v) neomycin sulphate/0.1% (w/v) bovine albumin for 48 
hours. The iodinated peptide was eluted with O.lM-Tris HC1 (pH 7.2)/0.2% 
(w/v) neomycin sulphate/0.1% (w/v) bovine albumin at 1 ml/min and 1ml
fractions collected. The labelled peptides were assayed and stored as for
125 .I-angiotensin II.
2.4 Animals
(a) General
Male Sprague-Dawley rats (325-350g) were used for all experiments. 
For experiments which did not involve alteration of sodium balance or drug 
administration, the rats were given tap water and a standard rat diet 
(Oxoid 41B). The animals were housed in groups of 3 or 4 and normally 12 
were used for each experiment.
(b) Manipulation of sodium balance and drug administration
For these experiments, a powdered foodstuff containing 0.002% 
(w/w) NaCl (Special Diet Services Ltd., Witham, Essex, U.K.) was used. 
Sodium chloride was added as required and mixed in thoroughly. Frusemide 
B.P. (Lasix) was administered by intraperitoneal injection. Captopril was
46
administered chronically as a 0.05% (w/v) solution in distilled water 
which was substituted for the drinking water. In acute studies captopril 
was administered intraperitoneally in 0.154M-NaCl. All captopril solutions 
were prepared fresh daily. The approximate intakes of NaCl and captopril 
were determined by daily weighing of the food and drinking fluid 
containers. The details of the diets and drug regimens are given in Table 
2.1.
(c) Tissue preparation and blood sampling
When blood sampling was not required, the rats were killed by a 
blow to the head. Otherwise, the animals were killed by decapitation and 
aortic blood collected within 5 seconds on ice. The blood was then 
immediately transfered to a tube containing 250ki.u. Trasylol/50 umols 
EDTA/lOumols o-phenanthroline in a total volume of 50ul and kept on ice. 
The blood samples were later centrifuged at lOOOg for 20 minutes at 2°C, 
and the plasma aspirated and stored at -20°C.
After sacrifice, the intestines were removed and placed in a petri 
dish containing 0.154M-NaCl on ice, and the mesenteric arterial arcades 
excised by blunt dissection. The fat in the centre of the mesentery was 
removed, the main artery and vein separated, and fine serrated-tip forceps 
used to strip adhering tissue from the arterial branches between the main 
artery and the mesenteric border of the intestine. This resulted in the 
removal of most of the fat and all venous tissue from the arterial 
arcades. The vessels were sectioned as close as possible to the wall of 
the intestine, and the excised arterial tissue kept in 0.154M-NaCl on ice 
during subsequent dissections.
2.5 Receptor-binding studies
(a) Preparation of the arterial membrane fraction
The mesenteric arterial arcades were cleaned of residual adherent 
fat in 0.25M-sucrose with a 30mm diameter smooth pestle (0.25mm clearance)
47
Table 2.1 
Dietary & drug protocols
GROUP
Captopril
Captopril
High salt
Normal
Low salt
Low salt
PROTOCOL
Chronic angiotensin converting enzyme blockade; 
captopril administered as 0.5 mg/ml solution in 
distilled water substituted for drinking water 
(normal salt diet)
(dosage 50-60 mg/kg/day)
(acute) Acute angiotensin converting enzyme blockade;
captopril administered in 500ul 0.9% (w/v) saline 
by intraperitoneal injection (normal salt diet) 
(dosage 50 mg/kg)
Sodium loading; 2% (w/v) saline substituted for 
drinking water and SDS foodstuff*, or SDS foodstuff 
containing 2.5% (w/w) NaCl and tap water 
(sodium intake 10-12 mmol/day)
Controls (normal salt diet); SDS foodstuff 
containing 0.1% (w/w) NaCl and tap water 
(sodium intake 0.5-1 mmol/day)
Sodium depletion; SDS foodstuff (0.002% w/w) NaCl
and distilled water
(sodium intake <0.01 mmol/day)
diuretic Sodium depletion; as low salt group plus frusemide 
4 mg/kg administered by intraperitoneal injection 
at commencement of diet
* powdered foodstuff from Special Diet Services Ltd. containing 
0.002% (w/w) NaCl
Teflon-glass homogeniser [Jencons (Scientific) Ltd., Bedfordshire, U.K.] 
[5-6 strokes, 6000 rev./min low-torque motor (Varilab type, Citenco Ltd., 
Borehamwood, Herts., U.K.)]. The tissue was then homogenised in 25ml 
of 0.25M-sucrose using a Polytron PT20S (Kinematica GmbH, Lucerne, 
Switzerland), setting 8 for 2x10 seconds. Care was taken to prevent 
heating of the tissue during homogenisation as this greatly reduced the 
binding capacity of the membrane material. The homogenate was immediately 
centrifuged at 2000g for 10 minutes, and the supernatant decanted and 
centrifuged as before. The membrane fraction was then obtained by 
centrifuging the second supernatant at 100,000g for 30 minutes. The pellet 
(300-400ug protein/arterial arcade) was resuspended using a small 
Teflon-glass homogeniser in a 50mM-Tris HC1 buffer and aliquoted into 
16x90mm polystyrene tubes for incubation and samples stored for subsequent 
assay of protein. All steps were carried out at 0-2°C.
(b) Incubations
The incubation mixture normally comprised lOOul of freshly prepared
membrane fraction suspension (50-70ug protein) and lOOul of 50mM-Tris HC1
125buffer containing 1% (w/v) bovine albumin and l-15000pg I-angiotensin
II. Where additional compounds were added (metal salts, proteinase 
inhibitors or competing peptides) tracer and additional compound(s) were 
each added in 50ul of 50mM-Tris HC1/1% (w/v) albumin, giving a total 
incubation volume of 200ul.
The composition of the Tris buffer was as follows: 
for normal assay
50mM-Tris HC1 (pH 7.35)/120mM-NaCl/3.6mM-KCl/1.8mM-MgCl2/4.8mM-CaCl2 
for high [Ca++] assay
50mM-Tris HC1 (pH 7.35)/120mM-NaCl/3.6mM-KCl/1.8mM-MgCl2/25mM-CaCl2 
for low [Ca++] assay
50mM-Tris HC1 (pH 7.35)/120mM-NaCl/3.6mM-KCl/2.5mM-EDTA/2.5mM-EGTA
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Non-specific binding was defined as radioactivity not displaced by lOuM- 
angiotensin II [added as 5ul of 400uM-angiotensin II in 50mM-Tris HC1/1% 
(w/v) albumin].
(c) Separation of receptor-bound and free radioactivity
Millipore 12-place sampling manifolds fitted with Whatman 0.2um 
cellulose nitrate (WCN type) membrane filters were used to separate 
receptor-bound and free radioactivity. The filters were pre-wetted with 
50mM-Tris HC1 (pH 7.35)/l% (w/v) albumin 15 minutes before use. The 
incubation mixtures were diluted by addition of 6.5ml ice-cold 50mM-Tris
HC1 (pH 7.35)/0.1% (w/v) albumin (filtration buffer) and filtered under
vacuum. The filters were rinsed with a second 6.5ml of filtration buffer 
and allowed to dry before removal for measurement of filter-trapped 
radioactivity. The filtration and washing process was completed in 30-40 
seconds. Where the filtrate immunoassay was used to estimate tracer 
degradation, the filtration buffer also contained 0.2% (w/v) neomycin 
sulphate. Results are presented as mean ± standard deviation for the 
difference between total and nonspecific binding:
i-6' (Tm - V  ± J(Ts + Ns>
where T , T are mean and standard deviation for total bindingm s 3
Nm' Ns are 1100911 standard deviation for non-specific binding
(d) Chromatographic analysis of receptor-bound radioactivity
For chromatographic analysis of receptor-bound and free radio­
activity, the reaction mixture was incubated for 60 minutes at 22°C and 
1ml of ice-cold 50mM-Tris HC1 buffer containing 1% (w/v) bovine albumin 
added. After centrifugation at 10,000g for 10 minutes, the supernatant was 
aspirated and an aliquot chromatographed as free radioactivity. The pellet 
was washed as before, resuspended in 200ul of the same buffer without 
albumin and transferred to a 100°C water bath for 5 minutes. Precipitated 
protein was removed by centrifugation and the supernatant chromatographed
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as receptor-bound radioactivity.
2.6 Radioimmunoassay of angiotensin peptides
(a) Preparation of antisera
Antisera to angiotensin peptides were prepared by immunising New 
Zealand white rabbits with a peptide-rabbit albumin conjugate as described 
by Morton et al (1976). The conjugate was prepared using the following 
reaction mixture:
4 mg peptide
60 mg l-ethyl-3-(3-dimethyl-amino-propyl)-carbodiimide HC1
2 mg rabbit albumin (crystalline)
in 2ml 0.154M-NaCl/0.2% (w/v) neomycin sulphate 
The reaction was allowed to proceed for 4 hours at room temperature after 
which the mixture was dialysed for 48 hours at 4°C against 4 changes each 
of 21 0.154M-NaCl/0.2% (w/v) neomycin sulphate using Visking tubing 
(Scientific Instrument Centre Ltd., London, U.K.). The conjugate was then 
diluted to 8 ml in saline/neomycin and stored as 0.25ml aliquots at -20°C.
Rabbits were immunised at 14 day intervals with 0.25ml of peptide- 
albumin conjugate emulsified with 0.25ml of Freund's adjuvant injected 
subcutaneously on the shoulder or hindquarters. Blood samples were drawn 
from the central ear artery and serum stored at -20°C. The presence of 
antibodies was determined by antiserum titration as described by Morton et 
al (1976). Antisera were used at final dilutions ranging from 1:4000 to 
1:60,000.
(b) Extraction of plasma samples
For radioimmunoassay of angiotensin II in rat plasma samples, the 
samples were first extracted using Sep-Pak cartridges (Waters
Associates, Cheshire, U.K.). Each cartridge was washed with 5ml of 
methanol then 5ml of distilled water, and the plasma passed through the 
cartridge at approximately lml/min. After a second wash with 5ml of
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distilled water, the angiotensin II was eluted with 2ml of methanol/water
(80:20 v/v). The extract was dried under a stream of air at 45°C, and the
residue stored at -20°C until assay. The recovery was determined using 
125I-angiotensm II and was consistently greater than 90%.
(c) Angiotensin radioimmunoassay
All reagents for angiotensin radioimmunoassay were prepared in 
50mM-Tris HC1 (pH 7.5)/0.3% (w/v) human serum albumin/0.2% (w/v) neomycin 
sulphate. The incubation mixture comprised:
200ul sample or known quantity of peptide (usually 200-3pg in two­
fold dilutions)
50ul radiolabelled peptide (usually 10pg)
200ul antiserum at appropriate dilution (1:1800-1:20,000)
Following incubation for 18 hours at 4°C, antibody-bound and free 
radioactivity were separated by addition of 1ml of dextran-coated charcoal 
(6.3g of Norit SXI charcoal and 0.125g of dextran T70 in 100ml of Tris HC1 
buffer) and centrifugation at 2000g for 7 minutes. The supernatant was 
aspirated and the (free) radioactivity absorbed to the charcoal pellet 
determined. The peptide content of the samples was determined by reference 
to a plot of percentage radioactivity bound against dose of unlabelled 
peptide. A typical radioimmunoassay standard curve is shown in Figure 2.1.
The standards used for the assay of angiotensin I and angiotensin 
II were the same as those used for the routine radioimmunoassay of these 
peptides in the Blood Pressure Unit laboratories.
Because of the marked rise in plasma angiotensin I concentration 
induced by converting enzyme inhibition and the 1.8% cross-reaction shown 
by the angiotensin II antiserum with this peptide, the plasma extracts 
from the captopril-treated rats were assayed for both angiotensin I and 
angiotensin II and the appropriate correction made. (The angiotensin I 
antiserum showed no discernable cross-reaction with angiotensin II).
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(d) Determination of specific activity
The specific activity of radiolabelled peptides for receptor 
binding studies was determined by self-displacement assay. This assay is 
based on the principle that in a radioligand binding assay, the ratio 
(bound ligand/total ligand) is determined by the total quantity of ligand 
(labelled and unlabelled) present. In each assay, a radioimmunoassay 
standard curve was set up using the radioligand to be assayed (diluted to 
the approximate required concentration) as tracer. In a second set of 
tubes, increasing quantities of radioligand only (usually 20X-Xpg in 
two-fold dilutions, where X is the quantity used as tracer for the 
standard curve) were incubated with antiserum. Following incubation and 
separation of bound and free ligand, the ratio (bound/total radioactivity) 
was calculated for all tubes. If nX pg of radioligand gave the same value 
of (bound/total) as X+D pg (where D is the value read from the abscissa of 
the standard curve), then X was calculated as D/(n-l) pg. The assay 
required that the antiserum did not distinguish between labelled and 
unlabelled ligand. This was verified by comparing the binding constants of 
the antiserum derived from the saturation binding curve using increasing 
concentrations of radioligand with those derived from the radioimmunoassay 
standard curve (a saturation binding curve in which the specific activity 
of a fixed amount of radioligand is reduced by addition of unlabelled 
ligand).
Each assay provided a set of standards which were counted for 
radioactivity at the same time as the samples from each receptor binding 
experiment, thus allowing count rates to be accurately related to molar 
quantities of radioligand. The results from a typical assay are shown in 
Figure 2.1.
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SATURATION BINDING CURVE (using radioligand under assay)
(1) (2) (3) (4) (5) (6) (7)
Total Total Bound B/T Dose D/(n-l) :Rel. slope
radioactivity (cpm) (as nX) radioactivity (cpm) (D) (X)
87809 ± 893 20.52 15515 ± 963 0.156
46351 ± 391 10.83 13288 ± 190 0.266 143.4 15.00 0.58
25468 ± 181 5.95 11009 ± 28 0.412 62.7 13.06 0.90
15223 ± 202 3.56 8731 ± 57 0.553 31.3 12.67 0.87
9896 ± 139 2.31 6742 ± 36 0.661 14.7 11.74 0.60
7187 ± 21 1.68 5338 ± 12 0.722 7.4 11.65 0.36
5710 ± 4 1.33 4392 ± 38 0.749 4.6 15.30 0.17
5084 ± 208 1.19 3934 ± 58 0.753 4.1 25.86 0.17
(2) Total radioactivity expressed as a multiple of X (X is the 100% value in the 
radioimmunoassay standard curve (below))
(4) Bound as a fraction of total
(5) Dose corresponding to each value of (B/T) read from radioimmunoassay 
standard curve (below)
(6) Peptide content of X (as pg unlabelled peptide)
(7) Relative slope of radioimmunoassay standard curve in region corresponding to 
(5), used as weight in calculating mean for (6)
MEAN ± S.D. for (6) (weighted)
13.14 ± 1.30 pg = 12.56 ± 1.23 fnpl (m.w. angiotensin II 1046)
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Figure 2.1 Determination of specific activity: self displacement assay
125of I-angiotensin II
The assay consisted of two parts; a saturation binding curve using the 
radioligand under assay (Table) and a radioimmunoassay standard curve with 
the radioligand as tracer (Figure ®  ). The calculations are shown in the 
table (columns 4-7) and are explained in Section 2.6d. Figure ®  shows 
Scatchard plots derived from the radioimmunoassay standard curve (solid 
markers) and from the saturation binding curve (open markers): the plots 
are superimposed, indicating that the antiserum did not distinguish 
between labelled and unlabelled peptides.
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(e) Quantitative determination of radioligand degradation
For quantitative estimation of radioligand degradation in receptor
binding studies, a 1ml sample of each filtrate (diluted if necessary) was
incubated for 18 hours at 4°C with 0.2ml of the appropriate antiserum.
Bound and free radioactivity were separated as described previously and
values of bound corrected for non-specific binding determined in parallel
incubations without antiserum. From a standard curve constructed using
pure radioligand the expected total radioactivity was calculated and the
fraction of radioligand remaining undegraded in the sample taken as
[total (expected)/total (measured)]. The results from a typical assay are
shown in Figure 2.2. Where angiotensin-related peptides were used in
displacement experiments, parallel incubations were performed without 
125I-angiotensin II and degradation of the peptides determined by 
radioimmunoassay.
2.7 Radioimmunoassay of plasma aldosterone
Aldosterone assays were performed by Miss M. Ingram in the Blood 
Pressure Unit laboratories according to the method of Fraser et al (1973). 
Plasma pooled from 4 rats was extracted into methylene chloride, 
chromatographed on paper and the aldosterone content determined by 
radioimmunoassay.
2.8 Chromatographic analysis of angiotensin peptides
Assessment of radiochemical purity was performed by descending 
paper chromatography using Whatman No. 2 paper and butan-2-ol/3% aq. NH^ 
(30:11, v/v) as mobile phase. Sheets of chromatography paper (57x23cm) 
were cut using a template into 12 lanes such that the distance from the 
sample origins to the end of the lanes was 46cm. After sample application, 
the paper was equilibrated with the solvent vapour for at least 4 hours 
before addition of solvent to the solvent trough. Chromatograms were 
allowed to run for 45 hours at room temperature, after which the paper was
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Figure 2.2 Filtrate immunoassay standard curve
Filtrate immunoassay standard curve for the quantitative determination of 
125I-angiotensin II degradation in receptor-binding incubations. Points 
represent mean ± s.d. for triplicate measurements of specific 125j_ 
angiotensin II binding to an angiotensin II-specific antiserum.
For a filtrate sample which gave a total count rate of 4000cpm and a bound 
count rate of lOOOcpm, the expected total count rate would be 1490cpm 
(from the standard curve) and the fraction of 125j_angi0tensin II 
remaining undegraded in the sample would be 1490/4000 = 0.373.
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dried and cut into 1cm strips for counting of radioactivity. The values 
for angiotensin II and the C-terminal hepta-, hexa- and pentapeptides were 
determined by chromatographing the unlabelled peptides and staining the 
paper with ninhydrin.
2.9 Bioassay of iodinated angiotensin II
125The biological activity of I-angiotensin II was assessed using
the pentobarbitone anaesthetised, pentolinium tartrate treated rat
preparation as described by Lever et al (1964). Bolus injections (50ul) of
1250.9% saline containing pure I-angiotensin II or angiotensin II amide 
(Hypertensin Ciba) were made via a cannula placed into the jugular vein 
and blood pressure was recorded via a carotid arterial catheter connected 
to an Elcomatic EM 751 pressure transducer and an Elcomatic EM 720 
recorder (Elcomatic Ltd., Glasgow, U.K.).
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CHAPTER 3 
STATISTICAL METHODS
3.1 Analysis of radioligand-binding data
Analysis of the receptor-binding data was performed as described 
below using a nonlinear regression computer program constituting part of 
the BMDP statistical package. The analysis was carried out on the Glasgow 
University ICL2988 computer.
3.2 Nonlinear regression
(a) General principles
The principles underlying the Gauss-Newton method of nonlinear 
regression have been described in detail by Wilkinson (1961) and are 
summarised below.
For a nonlinear equation in which there is a single parameter, p 
y = ftp)
an estimate, Pest/ will differ from the best-fit value, p,, by an unknown 
amount, q:
P- = Pest + q 
and therefore
yobs “ f(p!> - f(pest + q)- 
It may be shown that (as a close approximation)
yobs = f(Pest) + qf'(Pest> 
where yQ^ s is the observed value of y and f '  denotes differentiation with
respect to p (i.e. dy/dp).
Since
^pred “ ^^est^ 
where Ypre(j is the predicted value of y, then
yobs~ypred “ ^est^ 
and therefore
^ ^obs ^pred^ ^est^'
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Thus, by calculating the residual, Y0bs~Ypre$r an  ^the partial derivative, 
^pred^^est' 311 aPProximate value for q m y  be determined. The new 
estimate of the parameter m y  then be refined by further iterations. When 
the value of q is small compared to the value of pegt ("convergence"), the 
standard error of pegt is equal to that of q.
This may be extended to the case where there are n values of the 
dependent (observed) variable and m parameters
^obs ■ ypred = q(1) < 0 * 2  +....+ ^ p ^ d ^ s t
.
y£ 1  ' ypred = q(1) ^pred^esl +....+ q<m> ^ r i d ^ s t
*
y f^cs - ypred = q(1) dyp?id/dPest +....+ q<m> ^ r l d ^ e s t
and the values of q(l)-q(m) obtained by solving the system of linear
equations.
Any number of independent (controlled) variables m y  be present, and the 
only requirements are that an expression is given relating the dependent 
variable to the independent variable(s) and the parameters, and that 
initial estimates for the parameters are specified. The derivatives m y  be 
obtained by algebraic manipulation of the expression, or in complex 
systems where this is not possible, by numerical differentiation.
(b) Application
The data were analysed with a standard regression computer package 
[BMDP program PAR (derivative-free nonlinear regression)] (Dixon, 1981) in 
conjunction with FORTRAN programs specifying the function under study. 
Numerical integration of the differential equations forming the function 
was performed using Numerical Algorithms Group routine D02EAF.
The rate constants for radioligand (and in competition experiments, 
unlabelled ligand) degradation and for decay of the high-affinity sites
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were taken as known, leaving the forward and reverse rate constants and 
the receptor concentration for each class of sites to be estimated. In 
amalgamating results from several experiments, the receptor concentrations 
were taken to be proportional to membrane protein concentration and the 
constants of proportionality estimated.
Ihe program used for general analysis of kinetic and saturation 
binding experiments is given in Appendix A.I. In this program, fitting for 
two classes of binding sites is performed and the differential equations 
describing the reaction are therefore:
[*H] = radioligand concentration 
kdH = rate constant for [*H] decay
^dR = ra^e constant for [R^ ] decay 
An indexing system was devised which allowed several groups of data to be 
analysed under the assumption that receptor concentrations but not 
affinity varied between groups. This facility permitted smaller amounts of 
data (in each group) to be analysed than if analysis of each group was 
performed independently, and is referred to as the multiple receptor 
density method.
In the routine receptor assay, where the low-affinity component of 
binding was assumed to be linear with tracer concentration, the terms
d[*H]/dt = kf [^*H] [R,^  - kr^ [*HR1} + kf^[*H][R1] - kr [*HR ] + k^j[*H] 
d[R.]/dt = kf [*H][R,] - k [*HR,] + kj_,[R, ]
- d[R2]/dt = kf [*H][R2] - kr [*HR2]
2 2
d^HR^/dt = kf [*H] [R^ ] - kr [*HR1]
4-1 x *-1 ■"
d[*HR2]/dt = kf [*H][R2] - kr [*HR2]
where k , = forward rate constant
n
kr = reverse rate constant 
n
[Rn] = receptor concentration
[*HRn] = concentration of H-R complex
(bound radioligand)
n=l, high affinity site 
n=2, low affinity site
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relating to the low-affinity sites were omitted and a separate linear 
component estimated for each experiment. The program is given in 
Appendix A. 2 and part of the output produced by the program is shown in 
Figure 3.1.
For analysis of competitive binding curves, the low-affinity 
component of binding was ignored and the forward and reverse rate 
constants for tracer and competing ligands and the concentration of 
high-affinity sites estimated. An indexing system was devised allowing a 
metabolite of the competing ligand to be specified as one of the other 
competing peptides. This was used in the case of angiotensin I, where 
analysis showed that the metabolite (angiotensin II) was responsible for 
the observed displacement. The differential equations describing the 
reaction are therefore:
-d[*H]/dt = k*[*H][R] - k*[*HR] + k*[*H]
-d[CH]/dt = kj[CH][R] - k£[CHR] + k^[CH]
-d[mH]/dt = k™[mH][R] - k®[™HR] - k^[CH] + ^["h]
-d[R]/dt = k*[*H][R] - k*[*HR] + k^[CH][R] - k°[CHR] + k™[IIH][R]
- k ^ V ]  + kd[R]
d[*HR]/dt = k*[*H][R] - k*[*HR]
d[CHR]/dt = k^[CH][R] - k^ [CHR]
dt^HRl/dt = k™[mH][R] - k™[InEiR] 
where [*H] = concentration of radioligand
[CH] = concentration of competing ligand
= concentration of metabolite of competing ligand 
k| ,k* = forward and reverse rate constants for radioligand 
k^ ,k£ = forward and reverse rate constants for competing ligand 
k™ ,k™ = forward and reverse rate constants for metabolite 
[*HR] = concentration of bound radioligand 
[ CHR] = concentration of bound competing ligand
61
t10^ ] = concentration of bound metabolite
k| = rate constant for decay of [*H]
= rate constant for decay of [CH]
k^j = rate constant for decay of [mH]
The program used for analysis of competitive binding experiments is given 
in Appendix A.3.
For each data point supplied to the regression program, a weight 
calculated as (mean/standard deviation for replicate determinations of 
bound radioligand) was specified.
It was found that the analysis was more stable numerically when 
the regression program was estimating the logarithms of the rate 
constants. Consequently these results are presented as estimate ± standard 
error on a logarithmic scale.
The standard error for logtk^ /k^), i.e. log(K^ ) was calculated as;
where sr = asymptotic standard error for log(kr)
s^  = asymptotic standard error for log(k^ )
Pr£ = asymptotic correlation of log(kr) with log(k^ )
For any parameter, the difference in parameter estimates from two sets of
experiments was taken as significant when the difference between the point 
estimates exceeded two standard errors of the difference, i.e. when
where Ea and are the point estimates
sa and s^ are the corresponding standard errors
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Figure 3.1 The receptor assay: exairple results
The figure shows part of the print-out from the program used for the 
receptor assay. The parameters being estimated were; forward (KF) and 
reverse (KR) rate constants and concentration of sites per unit protein 
(RODP) for the high-affinity site, the reverse rate constant for the low- 
affinity site (KRL) and a linear low-affinity component of binding for
each of the three experiments contributing to the pooled data (L1DHDP...
L3DHDP). The scatter plots show; (left) observed (O) and predicted (P) 
values of bound l^Sj.^giotensin II (BND, the dependent variable) against 
initial tracer concentration (HO) and (right) the residuals (observed- 
predicted value of BND) against initial tracer concentration.
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CHAPTER 4
CHARACTERISATION OF THE VASCULAR ANGIOTENSIN RECEPTOR
4.1 Introduction
In this chapter the characterisation of the rat mesenteric artery
angiotensin receptor and the development of the receptor assay is
described. A comparison of the results of this study with those already
published is included in this chapter.
All experiments described in this section used arterial tissue
obtained from male Sprague-Dawley rats (325—350g) maintained on a standard
diet (Oxoid 41B). Unless othewise specified, all incubations were carried
out for 60 minutes at 22°C, using the normal assay buffer (50mM-Tris (pH
1257.35)/120mM-NaCl/3.6mM-KCl/4.8mM-CaCl2/l.8mM-MgCl2) and I-angiotensin 
II as tracer.
4.2 Specific binding as a function of membrane protein concentration
125Specific binding of 1-angiotensm II to the arterial membrane 
fraction was not linearly related to membrane protein concentration, 
indicating the presence of angiotensinase activity (Figure 4.1). Non­
specific binding consisted of two components; one which was linear with 
membrane protein concentration and (not shown) tracer concentration, and a 
constant component (for a given tracer concentration) due to absorption of 
tracer to the filter during separation of bound and free radioactivity. 
Specific binding ranged from 0.5 to 5% of total radioactivity, while non­
specific binding averaged 0.43 ± 0.05% (s.e.) of total radioactivity.
4.3 Tracer angiotensin II degradation
(a) Chromatographic analysis of bound and free radioactivity
Tracer degradation was identified by chromatographic analysis of 
the free radioactivity after incubation under standard conditions (Figure 
4.2B). The predominant metabolites were fragments not containing the C- 
terminal pentapeptide of angiotensin II and consequently were not expected
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125Figure 4.1 Binding of I-angiotensin II as a function of arterial 
membrane protein concentration
Incubation: 60 minutes at 22°c, initial 125l-angiotensin II concentration
0.3nM.
(A) points represent individual determinations of total and non-specific 
binding.
derived from data in(A), points represent mean ± s.d. for triplicate 
determinations.
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to bind to the angiotensin receptor (Bumpus et al, 1961) or to the 
antiserum used for angiotensin II immunoassay since both require this 
sequence for binding. This was confirmed by direct binding studies with 
the angiotensin II antiserum (see below) and by chromatographic analysis 
of eluted receptor-bound radioactivity (Figure 4.2C). The C-terminal 
heptapeptide (angiotensin III) was present as a component of the free 
radioactivity, but proportionately less was observed in the radioactivity 
eluted from the membrane. Similar results were obtained when -these
experiments were repeated at a higher initial tracer concentration (20nM), 
although the heptapeptide then comprised a larger proportion of the eluted 
radioactivity (Figure 4.2D). Under these conditions approximately 20% of 
the specifically bound tracer is associated with the low-affinity site 
(see below). Degradation of the free ligand still occured in the presence 
of 10uM unlabelled angiotensin II (not shown).
(b) Effect of proteinase inhibitors
A number of proteinase inhibitors were examined for their effect 
on both binding capacity and tracer angiotensin II degradation (Table 
4.1). The effects on binding were determined using short (15 minute) 
incubations since computer simulations indicated that the early phase of 
binding was relatively unaffected by changes in the rate of tracer 
degradation. The effects of the inhibitors on degradation of the tracer 
angiotensin II was assessed using standard 60 minute incubations. No 
inhibitor effectively prevented tracer degradation without adversely 
affecting binding capacity. Tracer degradation was therefore measured by 
filtrate immunoassay and the appropriate corrections made in the analysis 
of the binding data.
(c) Accuracy of the filtrate immunoassay
The accuracy of the filtrate immunoassay was determined by
125allowing a quantity of 1-angiotensm II to be completely metabolised by
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Figure 4.2 Qiromatographic analysis of bound and free radioactivity
Incubation: 60 minutes at 22°C, initial "^I-angiotensin II concentration
0.2nM (A-C), 20nM (D).
®  control incubation, no membrane fraction.
(b) free radioactivity after incubation with 92ug/200ul arterial membrane 
fraction.
©  radioactivity eluted from the membrane fraction after incubation with 
0.2nM 125i_angi0tensin II.
©  radioactivity eluted from the membrane fraction after incubation with 
20nM l^i-angiotensin II.
Identical results for ®  and (b) were obtained when the initial tracer 
concentration was 20nM (not shown). The broken lines in ©  and ©denote 
non-specific binding determined in parallel incubations. The running 
positions of angiotensin II (Ang II) and the C-terminal hepta- (C~_fi), 
hexa- (C3_g) and penta- ©_g) peptides is indicated.
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Table 4.1
Effect of proteinase inhibitors on binding and degradation 
125of I-angiotensin II
Inhibitor Binding Apparent tracer decay
rate constant 
(% of control) (% of control)
I----------------------------------------------------------------------------------1 I 1 I----------------------- 1
EDTA 57 ± 9 51
EGTA 81 ± 8 89
Dithiothreitol 67 ± 5 100
PMSF/glucagon 112 ±10 75
Tos-Phe-CH2Cl 86 ± 4 75
STI 113 ± 5 95
Trasylol 105 ± 5  94
Trasylol/Tos-Phe-CH2Cl/STI/glucagon 76 ± 4 71
Trasylol/Tos-Phe-CH9Cl/STI/glucagon/
PMSF 77 ± 5 54
Di-isopropyl phosphite 37 ± 11 11
HgCl2 not done 0
The effect on binding was determined using 15 minute incubations at 22°C
125(results for triplicate determinations ± 1 s.d.), initial I-angiotensin 
II concentration 0.3nM; the effect on tracer degradation was determined 
using 60 minute incubations, chromatography of the free radioactivity and 
calculation of peak areas.
Concentration of inhibitors: EDTA, 5mM; EGTA, 5mM; dithiothreitol, 0.5mM; 
glucagon, lOuM; Tos-Phe-CH2Cl, 0.5mM; soya trypsin inhibitor (STI), 15uM; 
Trasylol, lOOk-i.u./ml; phenylmethylsulphonylfLuoride (PMSF) O.lmM; di­
isopropyl phosphite, 20mM; HgCl2, ImM.
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the membrane fraction preparation (2 hours incubation at 37°C with 460ug 
of membrane protein/ml). The angiotensinase enzymes were then inactivated 
by heating at 100°C for 5 minutes and precipitated protein removed by
centrifugation. The resulting metabolite preparation was then mixed with
125 125pure I-angiotensin II such that the I-angiotensin II represented 0,
20, 50, 75 or 100% of the total radioactivity. Samples of each preparation
were then subjected to immunoassay or chromatographed and the proportion
125of radioactivity present as 1-angiotensm II determined by calculation 
of peak areas. The results shown in Table 4.2 indicate that the assay 
allows reliable measurement of tracer degradation.
4.4 Stability of the receptor preparation
The stability of the receptor preparation was assessed by pre­
incubating the arterial membrane fraction without tracer angiotensin II
125 oprior to incubation with 0.3nM- I-angiotensin II for 60 minutes at 22 C
(Figure 4.3). The receptor preparation was stable at 22°C (8% loss in 
binding capacity at 60 minutes) but not at 37°C (30% loss‘after 60 
minutes). No change in binding capacity was detected over a 4 hour pre­
incubation on ice.
4.5 Kinetics of specific binding
125Specific binding of I-angiotensin II to the membrane fraction
was time and temperature dependent (Figure 4.4). At 22°C binding began to
plateau within 60 minutes of incubation while at 37°C binding was maximal
at approximately 20 minutes of incubation and subsequently declined
probably due to the more rapid metabolism of the tracer angiotensin II at
this temperature (Figure 4.4). In all such experiments tracer angiotensin
II concentration declined in a simple exponential manner.
125Dissociation profiles of specifically bound I-angiotensin II 
from the membrane fraction were identical when the forward (association) 
reaction was blocked by dilution (1:32) or addition of excess unlabelled
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Table 4.2 
Accuracy of the filtrate immunoassay
125I-angiotensin II (% of total radioactivity)
.A .r
(a) Expected (b) Immunoassay (c) Chromatographic
_A_____   A______ _ _______
( V  ( f
100 100 96
75 • 78 ± 10 75
50 47 ± 10 54
20 18 ± 8 26
0 -8 ± 5 <10
125I-angiotensin II was mixed with a completely metabolised tracer
125preparation such that 1-angiotensm II represented varying proportions 
of the total radioactivity, (a) Expected proportion; (b) proportion as 
determined by immunoassay (mean ± s.d. for 6 replicates); (c) proportion 
as determined chromat©graphically by calculation of peak areas.
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Figure 4.3 Stability of the receptor preparation
The arterial membrane fraction was preincubated as shown prior to a 60 
minute incubation at 22°c with 0.3nM "^^i-angiotensin II. Points represent 
mean ± s.d. for 4-6 determinations.
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angiotensin II (to 5uM) and deviated markedly from simple exponential 
decay indicating heterogeneity of binding sites and the absence of 
site-site co-operative effects. Similar results were obtained at 22°C and 
37°C (Figure 4.5).
4.6 Saturability of specific binding
125Specific binding was saturable but only at I-angiotensin II 
concentrations which were extremely high in relation to plasma angiotensin 
II concentrations in the rat (Figure 4.6). Although not quantitatively 
applicable, Scatchard transformations (Figure 4.6, inset) of the binding 
data were markedly curvilinear, consistent with the results from the 
dissociation experiments indicating heterogeneity of binding sites.
4.7 Analysis of the binding data
Application of non-linear regression methods to saturation binding 
data such as that shown in Figure 4.6 allowed determination of forward 
rate constants and binding site concentrations, but the reverse rate 
constants were poorly estimated. Computer simulations indicated that the 
shape of such binding curves is influenced to a relatively small extent by 
changes in dissociation rates. There was also a high degree of 
correlation between the forward and reverse rate constants. Analysis of 
saturation and dissociation curves together permitted determination of all 
binding constants (Table 4.3 column(a)). Based on the kinetic constants 
determined from saturation binding curves, the low-affinity component of 
binding in the time-course experiments could reasonably be approximated by 
a straight line parallel to the abscissa (Figure 4.4, broken line). This 
approximation was necessary in order to analyse the data from such 
experiments, using a four parameter fitting procedure (three parameters 
relating to the high-affinity site and the ordinate intercept for the 
linear component of binding. This approach yielded kinetic constants for 
the high affinity site in agreement with those derived from saturation
72
21
TDaZDO
-O
10-
'5 B7°Cc
I/)
£Z
QJ
“o
Incubation time (minutes)
100-1
.0
1  80-
22°C
‘<zn
<  20-  1
iA-1
TT
Incubation time (minutes)
125Figure 4.4 Binding and degradation of I-angiotensin II as a function
of time and tenperature
(A) Time and temperature dependence of specific binding of 1^i-angiotensin 
II. Points represent mean ± s.d. for 3 determinations. The broken line 
denotes the predicted low affinity component of binding at 22°C. 
Initial 125j_angi0tensin II concentration 0.3nM.
(b) Degradation of l25I-angiotensin II determined in the same experiment by 
filtrate immunoassay. Points represent mean ± s.d. for 3 replicates.
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125Figure 4.5 Dissociation of specifically bound I-angiotensin II from
the arterial membrane fraction as a function of time and 
temperature
The arterial membrane fraction was incubated with 0.3nM -^i-angiotensin 
II for 60 minutes at 22°C or 20 minutes at 37°C and the forward reaction 
then blocked by addition of excess unlabelled angiotensin II (to 5uM, 
closed markers) or dilution (1:32, open markers) and the incubation 
continued as shown. Points denote mean ± s.d. for 2-4 determinations.
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125Figure 4.6 Binding of I-angiotensin II to the arterial membrane
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determinations.
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Insets show Scatchard transformations of the binding data.
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binding curves (Table 4.3 column(b)). The binding constants at 37°C 
(Table 4.3 column(d)) were obtained by simultaneous analysis of all 
experimental data using the curve-fitting procedure for two classes of 
binding sites.
4.8 Comparison with other studies
There are few published reports regarding angiotensin receptors in 
rat mesenteric artery smooth muscle (Gunther et al, 1980a,b; Aguilera & 
Catt, 1981; Wright et al, 1982; Schiffrin et al, 1983c; Paller et al, 
1984); a summary of the results from these studies is given in Table 4.4. 
Gunther et al (1980a) observed no degradation of the tracer angiotensin II 
during incubation and hence did not use proteinase inhibitors, while in 
the other studies the use of EDTA and/or dithiothreitol as angiotensinase 
inhibitors was required (dithiothreitol in combination with glucagon or 
EDTA is effective in inhibiting the angiotensinase enzymes in adreno­
cortical membranes, and does not appear to interfere with angiotensin II 
binding in this tissue). It is possible that the chromatographic methods 
used by Gunther et al (1980a) did not have sufficient resolution to detect 
degradation of the peptide (thin layer chromatography is most often used 
for this purpose); this may account for the 10-fold lower affinity 
reported by these authors, since ligand degradation in binding studies 
will affect mainly the estimate of affinity (Ketelslegers et al, 1975). As 
shown in Table 4.1, dithiothreitol was ineffective and EDTA only partially 
effective in inhibiting destruction of the angiotensin II, and both agents 
are inhibitory on the receptor. The other studies may therefore be doubly 
compromised by ligand degradation and inadvertant inhibition of 
angiotensin binding. Alteration of the incubation medium ionic composition 
can also have a major effect on the receptor (Section 4.12). However, 
these reports are largely in agreement, with values in the range 
0.1-lnM and receptor concentrations in the range 50-100 fmol/mg protein
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Table 
4.3 
125
Binding 
constants 
for 
I-angiotensin 
II
(this study included), and the differences may be accounted for by 
methodological factors.
Paller et al (1984) observed a considerably higher receptor 
concentration; this is may be due to a sex difference since these authors 
used male and female rats while male rats (Sprague-Dawley in all cases) 
were used in all the other studies. In a preliminary experiment, female 
rats were used and the receptor concentration found to be approximately 
2.5-fold higher than in male animals (Table 4.4).
In none of the studies cited above was a low affinity class of 
binding sites observed; this may be due to the use of lower tracer 
concentrations, which in most cases did not exceed 5nM for saturation 
binding curves.
4.9 Specificity
Because of the complexity of this radioligand-binding system, 
initial attempts to demonstrate specificity for angiotensin-related 
peptides were based on direct binding studies using radiolabeled peptides.
However, these studies were hampered by the low affinity of even the best
1 8  1 8  antagonists (sar ile angiotensin II, sar thr angiotensin II), and it
was necessary to carry out competitive binding studies using a low
125concentration of I-angiotensin II (O.lnM) which gave a negligible 
proportion (<2%) of the bound radioligand associated with the low- 
affinity site (Figure 4.7). The affinity series (equilibrium constants)
after correction for tracer and competing ligand degradation was;
125 1 8I-angiotensin II = angiotensin II > angiotensin III > sar ile
angiotensin II > sar1 thr^  angiotensin II > sar1 gly^  angiotensin II >
1 8angiotensin II C3_g hexapeptide > sar ala angiotensin II > angiotensin 
II C^_g pentapeptide »  angiotensin I = bradykinin = arginine vasopressin. 
The sarcosine1 peptides were found to be resistant to degradation by 
immunoassay and this was confirmed by chromatography (Figure 4.8). The
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other angiotensin peptides were all degraded at approximately the same
rate; in the case of angiotensin I, binding constants could not be
calculated as angiotensin II production during incubation accounted for
the observed displacement (approximately 5% of the angiotensin I was
converted to angiotensin II and another 45% reduced to non-immunoreactive
metabolites). The computed affinities for the angiotensin peptides are
125given in Table 4.5. The kinetic constants for I-angiotensin II were in 
good agreement with those obtained by the more direct methods described 
above.
The discrimination between angiotensins I, II, III, and the C-
terminal hexa- and pentapeptides parallels the physiological activities of
these peptides, with angiotensin III possessing one third the pressor
activity of the octapeptide and the other peptides essentially inactive
(Schwyzer, 1963; Bumpus, 1977; Carey et al, 1978). In Figure 4.7, the
sarcosine^ peptides appear almost equipotent with angiotensin II in 
125displacing I-angiotensin II from the high affinity site; similar
results were obtained by Gunther et al (1980a) and Aguilera & Catt (1981).
However, correction for degradation of the natural peptides shows that the
affinity of the receptor for the analogues is substantially lower than for
angiotensin II. This is consistent with the results of Pettinger et al
1 8(1975) who found that extremely high plasma concentrations of sar ala 
angiotensin II (30-300ng/ml) were needed to inhibit pressor response to
o
infused angiotensin II in the rat. The finding that the ile peptide has 
the highest affinity of all the analogues is also consistent with other 
pharmacological studies (Davis et al, 1974). These results also support 
the view expressed in Section 4.8 that the results obtained by Gunther et 
al (1980a) and Aguilera & Catt (1981) may have been compromised by 
unrecognised tracer angiotensin II degradation.
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Distance from origin (cm)
Figure 4.8 Resistance of sar cosine^ peptides to degradation:
verification by chromatography
Chromatographic analysis of free radioactivity after incubation of 0.3nM 
125i_sarl thr^  angiotensin II with 87ug/200ul arterial membrane fraction 
for 60 minutes at 22°c. Broken line denotes control (no membrane fraction) 
incubation. Similar results were obtained for other sari antagonists (not 
shown).
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Table 4.5
Binding constants for angiotensin-related peptides
log [kf (M_1.s_1)] log [kr (s-1)] log [Kd (M) ]
( A-------------- V ----------  ------------V  * ^
Peptide
125I-angiotensin II
angiotensin II
angiotensin III
angiotensin II
Cg_g hexapeptide
angiotensin II
C4-8 
1 8sar ile angiotensin II 
1 8sar thr angiotensin II 
1 8sar gly angiotensin II 
1 8sar ala angiotensin II
6.079 ± 0.076 -4.010
5.934 ±0.106 -4.139
5.505 ± 0.000* -3.961
4.323 ± 0.065* -3.696
2.286 ± 0.002* -3.154 
5.423 ± 0.120* -3.569 
4.989 ± 0.217* -3.211
5.079 ± 0.111* -3.018 
4.850 ± 0.000* -3.077
±0.155 -10.09 ±0.13 
± 0.210 -10.07 ± 0.20 
± 0.186 -9.47 ± 0.19*
± 0.280 -8.02 ± 0.26*
± 0.057* -5.44 ± 0.06* 
± 0.079* -8.99 ± 0.13* 
± 0.215* -8.20 ± 0.25* 
± 0.066* -8.08 ±0.09*
± 0.544 -7.93 ± 0.54*
the data depicted inResults obtained by nonlinear regression analysis of
Figure 4.7, presented as point estimate ± standard error. Parameter
125estimates differing significantly from that for I-angiotensin II are 
indicated (*).
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4.10 The receptor assay
While it was possible to demonstrate complete saturability of 
125 .I-angiotensin II binding to the arterial membrane fraction, this was 
technically difficult due to the small difference between total and non­
specific binding obtained when tracer concentrations in excess of lOnM 
were used. Since it was unlikely that the low affinity sites (K^ =50nM) 
could interact with angiotensin II at physiological concentrations, the 
routine receptor assay (for the investigation of physiologically relevant 
changes in receptor status) was directed only at the high affinity sites.
The receptor assay consisted of a saturation binding curve for
125I-angiotensin II (10 concentrations, 0.05-10nM) and a dissociation time 
course curve (3 time points over a 2 hour period) since, as noted above, 
saturation curves alone did not usually allow determination of reverse 
rate constants. This approach allowed accurate estimation of the binding 
constants for the high affinity site but those relating to the low 
affinity site were poorly estimated (Table 4.3 column(b)). Over this 
concentration range, binding to the low affinity sites is virtually 
proportional to tracer concentration (Figure 4.6). It was therefore only 
necessary to determine the coefficient of proportionality rather than the 
binding constants for a second class of sites. In the analysis of the 
assay results, the parameters to be estimated were; the forward and 
reverse rate constants and concentration for the high affinity sites, the 
coefficients for the linear low affinity component of binding (a separate 
coefficient for each experiment contributing to the pooled data, since 
membrane protein concentration varied between experiments and specific 
binding was not linearly related to membrane protein concentration) and 
the reverse rate constant for the low affinity sites (due to the 
dissociation time course curve) (see Appendix A.2 and Figure 3.1). This 
method yielded binding constants for the high affinity site in close
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agreement with those obtained by the direct methods described above (Table
4.6).
4.11 Biological activity of iodinated angiotensin II
The competitive binding experiments (Section 4.9) showed that the
125receptor did not discriminate between I-angiotensin II and the native
peptide (Table 4.5). Gunther et al (1980a) also found the mesenteric
125 3artery receptor to display equal affinity for -1- and H- labelled 
angiotensin II and similar results have been obtained for the bovine 
adrenocortical receptor by Glossman et al (1974c). These findings conflict 
with earlier reports that the tyrosyl monoiodinated peptide retains 25-70% 
of the biological activity of the native peptide, as determined by pressor 
assay in rats and contractile response assay using visceral and uterine 
smooth muscle (Lin et al, 1970; Kurcbart et al, 1971; Papadimitriou & 
Vforcel, 1974).
It was therefore of interest to re-examine the biological activity
of the iodinated peptide. This was achieved by measuring the pressor
125responses to bolus injections of pure I-angiotensin II and angiotensin
II (Hypertensin Ciba) (Figure 4.9) in the anaesthetised, sympathetically
blocked rat using the methods of Lever et al (1964). The results indicate
that the iodinated peptide retains full biological activity. The labelled
peptide actually appeared to be slightly more potent than angiotensin II 
125(5ng I-angiotensin II gave a pressor response equivalent to that of 7ng
125angiotensin II); this may be due to the higher purity of the I-
angiotensin II obtained from New England Nuclear. It seems likely that
the reduced activity of the iodinated peptide in the earlier studies was
due to impurity of the preparation; in these earlier studies the peptide
was purified by ion-exchange chromatography on soft gels, whereas the 
125I-angiotensin II obtained from New England Nuclear is purified by 
reverse-phase high performance liquid chromatography.
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0o' 51 io1 1? 201 251 301 351
Time (minutes)
125Figure 4.9 Bioassay of I-angiotensin II
Angiotensin II amide (Hypertensin Ciba) or -*-^ I^-angiotensin II were given
as bolus injections through a jugular vein cannula and changes in arterial
pressure monitored via a carotid artery catheter and pressure transducer.
1) 5ng Hypertensin 2) 4ng Hypertensin
3) 4ng Hypertensin 4) 15ng x^I-angiotensin II
5) 7ng Hypertensin 6) 15ng JI-angiotensin II
7) lOng Hypertensin 8) 9ng Hypertensin
9) 5ng I-angiotensin II 10) 9ng Hypertensin
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4.12 Factors influencing specific binding
125The effects of various cations on binding of 1-angiotensm II 
were investigated (Figure 4.10). As in Section 4.3b, short incubations (15 
‘minutes) were used to minimise effects of alteration in tracer degradation 
rate on binding. Sodium showed a biphasic effect, enhancing binding in the 
absence of other cations with a maximum effect at lOOmM. Although the 
effect of sodium on binding was small, this biphasic response was seen 
consistently. In the presence of 150mM sodium, potassium and the potassium 
channel blocking agent tetraethylammonium also gave a biphasic effect 
while potassium alone simply increased binding to a small extent. In 
contrast to the weak effects of monovalent cations, divalent cations had a 
pronounced effect on binding, calcium being most potent. When maximal 
stimulation of binding by calcium had been achieved, a similar but more 
marked biphasic effect of sodium was observed, suggesting that these ions 
act by independent mechanisms, but at concentrations greater than lOOmM 
sodium can interfere with the action of calcium. In the absence of added 
cations, chelating agents were inhibitory, suggesting that calcium and/or 
magnesium tightly bound to the cell membrane is carried through the tissue 
processing procedures. Using the methods of Gunther et al (1980a), Wright 
et al (1982) obtained qualitatively very similar findings. The inhibitory 
effect of lithium may be due to displacement of bound calcium; after 
pre-treatment of the membrane fraction with EDTA/EGTA, the inhibitory 
effect of lithium was greatly reduced, and the stimulatory effect of 
calcium was abolished in the presence of 25mM lithium (results not shown). 
Wright et al (1982) also found lithium to be inhibitory and to abolish the 
inhibition of binding by guanine nucleotides (which was dependent on 
divalent cations).
To determine whether calcium affected the receptor concentration or 
affinity, the ionic content of the assay incubation medium was modified as
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described in Section 2.5b. The results (Table 4.6) show that calcium 
influences receptor number without change in affinity. Similar findings 
have been reported for cardiac (Wright et al, 1983; Baker et al, 1984) and 
uterine (Douglas et al, 1982) smooth muscle, but Wright et al (1982) 
report that both calcium and sodium increase the affinity of the 
mesenteric artery receptor. This discrepancy may be accounted for by the 
methodological factors discussed in Section 4.8. The effect of calcium was 
also completely reversible; exposure of the arterial membrane fraction to 
high [Ca++], recovery by centrifugation and assay in low [Ca++] gave a 
receptor concentration identical to that obtained when the assay was 
carried out directly in low [Ca++] (Figure 4.11).
In all tissues where the effect of guanine nucleotides on the 
binding of angiotensin II has been investigated, an inhibitory action was 
observed (see Chapter 1). This also applies to the rat mesenteric artery 
preparation, and is specific for GTP and the non-hydrolysable analogue 
Gpp(NH)p (Figure 4.12). Gpp(NH)p appears 30-fold more potent, indicating 
rapid hydrolysis of GTP by the membrane fraction. Wright et al (1982) also 
report an inhibitory effect (reduction in affinity) of guanine nucleotides 
in this tissue, and have proposed that GTP and mono/divalent cations 
interact to regulate the receptor. However, receptor assays in low, normal 
and high [Ca++] in the presence of lOOuM Gpp(NH)p suggest that GTP and 
calcium act through independent mechanisms; affinity was reduced 10-fold 
in all cases, but receptor number was still influenced by calcium although 
it was about 30% less (all cases) than in the absence of Gpp(NH)p (Table
4.6). The action of guanine nucleotides appears to require Mg++ (Wright et 
al, 1982; Gilman, 1984). For this reason, the effect of Gpp(NH)p under low 
[Ca++] conditions was determined in low [Ca++] buffer without chelating 
agents and containing 200uM MgC^ after washing the membrane fraction with 
the EDTA/EGTA-containing assay buffer.
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Figure 4.10 Effect of mono- and divalent cations chi specific binding of 
1251-angiotensm to the arterial membrane fraction
Incubation: 15 minutes at 22°C, initial -^I-angiotensin ii concentration 
0.3 nM. Points denote mean ± s.d. for 3-6 determinations.
@  Open markers; effect of sodium (25-150mM) and potassium or tetraethyl- 
ammonium (TEA) (2, 5, 10 & 50mM) in the presence of 150mM sodium. Closed 
markers; as before but in the presence of 25mM calcium.
(b) Effect of divalent cations, chelating agents, potassium and lithium.
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Figure 4.11 Reversible effect of calcium on apparent receptor density
The arterial membrane fraction was alternately suspended in low-[Ca++] and 
high-[Ca++] assay buffer, and at each suspension samples were taken for 
assay of protein and measurement of 125I-angiotensin II binding. Between 
suspensions the membrane fraction was recovered by centrifugation for 30 
minutes at 100,000g at 10°C in the buffer used for the previous suspension. 
In each experiment, each sample of the membrane fraction was incubated with 
two concentrations of ^^I-angiotensin II (60 minutes at 22°C); these 
concentrations varied between experiments, allowing complete saturation 
binding curves to be constructed over a number of experiments. The figure 
shows the changes in receptor density (point estimate ± standard error) 
determined by analysis of data from 4 experiments using the multiple 
receptor density method (Section 3.2b). No change in receptor affinity was 
observed.
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100-1
ATP (a)
80-
GTP
50-
40-
Gpp(NH)p
w
Nucleotide concentration (jjM)
125Figure 4.12 Effect of nucleotides on I-angiotensin II binding
Incubation: 15 minutes at 22°C, initial 125j_angi0tensin II concentration 
0.3nM. Points denote mean ± s.d. for 2-4 determinations.
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rTable 4.6
++Effect of Ca and Gpp(NH)p on the mesenteric artery angiotensin receptor
-Gpp(NH)p
_________  _A_______________
Assay [Ca ]
High
Normal
Low
log [kf (M 1.s 1)] log [kr (s 1)]
_A_r  ^ r
6.023 ± 0.080 -3.910 ± 0.310
Receptor cone11 
(fmol/mg)
^  f   ^
5.897 ± 0.052 
5.802 ± 0.136
-4.208 ± 0.165 
-3.795 ± 0.013*
156.2 ± 4.6*
102.2 ± 4.2 
49.9 ± 4.0*
Assay [Ca++]
High
Normal
Low
+Gpp(NH)p (100UM) 
— A____________
log [kf (M 1.s 1)] log [kr (s -1)]
r  ^ \
' 4.729 ± 0.134 -3.967 ± 0.083
4.969 ± 0.108 
4.631 ± 0.277
-4.044 ± 0.023 
-4.294 ± 0.660
Receptor cone 
(fmol/mg) 
 A___
n
( s\ 
115.8 ± 18.4
69.1 ± 15.5
29.0 ± 12.2*
The composition of the assay buffer was modified as described in Section 
2.5b, and where required Gpp(NH)p was added. The results were obtained 
using the receptor assay (Section 4.10) and are presented as point estimate 
± standard error. For experiments in the absence of Gpp(NH)p, n=5 (each), 
with Gpp(NH)p, n=3 (each). A parameter estimate differing significantly 
from that obtained with the normal [Ca++] assay in each group (with or 
without Gpp(NH)p) is indicated (*).
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CHAPTER 5
REGULATION OF THE VASCULAR ANGIOTENSIN RECEPTOR
5.1 Introduction
As described in Chapter 1, regulation of the smooth muscle angio­
tensin receptor usually involves a change in receptor number directionally 
opposite to the change in plasma angiotensin II concentration. In view of 
the effect of Ca++ on receptor number described in Section 4.12 it was of 
interest to examine the role (if any) of Ca++ in receptor regulation. 
Alteration of sodium balance has long been associated with reciprocal 
changes in plasma angiotensin II concentration and pressor sensitivity to 
the peptide, and provided a convenient experimental system in which to 
study the regulation of the mesenteric artery receptors.
5.2 Manipulation of plasma angiotensin II concentration
Sustained alterations in plasma angiotensin II concentration were 
brought about through variation of sodium balance and by administration of 
captopril, an angiotensin converting enzyme inhibitor (Table 2.1). The 
effect of these dietary and drug regimens is shown in Figure 5.1. As 
expected, sodium depletion caused an increase in plasm angiotensin II 
concentration which was considerably enhanced by administration of a 
diuretic at the commencement of the low salt diet. Sodium loading and 
converting enzyme blockade were equally effective in suppressing plasma 
angiotensin II concentration.
| |
5.3 Associated receptor changes: normal [Ca ] assay
Little is known regarding the time course of receptor changes 
following perturbation of plasma angiotensin II concentration. Bellucci & 
Wilkes (1984) observed a progressive change in glomerular angiotensin 
receptor density for five days after alteration of sodium balance in the 
rat and a similar course is apparent in the adrenal cortex (Aguilera et 
al, 1980b). The effects of the dietary and drug manipulations were
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therefore determined at two (possible early phase), five and twelve 
(established phase) days after commencement of each protocol. The changes 
in receptor density determined with the normal [Ca++] assay are shown in 
Figure 5.2. No consistent change in receptor affinity was seen (Table
5.1). Agreeing with the generally accepted model of vascular angiotensin 
receptor regulation, reciprocal changes in receptor density were observed 
when plasma angiotensin II concentration was elevated by sodium depletion 
or suppressed by converting enzyme blockade. However, sodium loading 
(which was equally effective with captopril in suppressing plasma 
angiotensin II concentration) caused a slow fall in receptor density. 
Sodium loading has previously been shown to have no effect on the uterine 
angiotensin receptor (Devynck et al, 1979) and earlier reports of receptor 
up-regulation with suppression of plasma angiotensin II concentration had 
used bilateral nephrectomy (Devynck & Meyer, 1976). Aguilera & Catt (1981) 
observed up-regulation of the mesenteric artery receptors after 4 days of 
sodium loading [0.3% (w/w) NaCl diet] but Schiffrin et al (1983c) have 
reported a slight fall (not significant by their methods) in receptor 
density in this tissue with 10 days of sodium loading (drinking 1% 
saline). Gunther et al (1980b) did not investigate the effect of sodium 
loading.
The sodium loaded animals showed no obvious sign of ill-health 
(such as weight loss) due to drinking saline, possibly because the large 
rats used in this study were better able to tolerate a high sodium intake. 
To exclude the possibility that a non-specific effect was responsible for 
the fall in receptor density, the five and twelve day sodium loading 
experiments were repeated with the salt administered in the food only 
(Table 2.1). The results were identical with those for the saline-drinking 
animals (Table 5.1).
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Figure 5.1 Effect of dietary and drug regimens on plasma angiotensin 
II and aldosterone concentrations
plasma angiotensin II concentration, points denote mean ± s.e. for 
at least 12 rats.
plasma aldosterone concentration, points represent mean for 2 or 4 
determinations, each determination made using plasma pooled from 4 
rats. At 12 days, the difference between Captopril and High salt 
groups is significant (p<0.05, unpaired t-test)
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plasma angiotensin II concentration: normal [Ca ] assay
Results obtained using the receptor assay (Section 4.10), presented as 
point estimate ± standard error for at least 3 experiments (12 rats per 
experiment). Actual values are given in Table 5.1. The effect of acute 
captopril administration (1 hour before sacrifice) is shown at Time 0.
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Gunther at al (1980b) have shown that the decrease in mesenteric 
artery angiotensin receptor number associated with sodium depletion is 
prevented by converting enzyme blockade. Preliminary experiments (not 
shown) have given results agreeing with this observation. Also, Aguilera & 
Catt (1981) have shown that infusion of angiotensin II causes a 
dose-dependent fall in receptor density in this tissue. These findings 
indicate that the effect of sodium depletion on receptor density is due to 
the rise in plasma angiotensin II concentration. The differing effects of 
sodium loading and captopril suggest that some other factor also acts on 
the vascular receptors and that this factor is linked with sodium balance. 
Schiffrin et al (1983c) have proposed that aldosterone may regulate the 
vascular receptors. Plasma aldosterone concentration was consistently 
higher during captopril administration than in sodium loading but only 
significantly so at twelve days (Figure 5.1). This may have been due to a 
change in potassium balance.
Atrial natriuretic peptide (ANP) has been reported to antagonise 
both the vascular (Kleinert et al, 1984) and adrenocortical (Chartier et 
al, 1984) responses to angiotensin II in vitro, and the natriuretic 
activity of this peptide suggests a role in the regulation of sodium 
balance. Using an assay recently developed in the Blood Pressure Unit 
(B.J. Leckie, G.D. McIntyre, M. Richards & G. Tonolo) no change in plasma 
ANP concentration with alteration of sodium balance was evident; however 
this assay has not been fully validated, and there may be a high molecular 
weight substance in plasma which interferes with the assay (results not 
shown).
5.4 Prior receptor occupancy
To exclude the possibility that endogenous angiotensin II bound to 
the receptors and carried through the tissue processing procedures could 
interfere with the receptor assay, rats maintained on a normal sodium diet
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were given captopril (50mg/kg) by intraperitoneal injection 1 hour before
sacrifice and removal of arterial tissues for receptor assay. No effect on
the receptors was-observed (Figure 5.2). The lag between the change in
plasma angiotensin II concentration and the change in receptor density
also suggests that prior receptor occupancy by endogenous angiotensin II
did not account for the observed changes in receptor density.
||
5.5 Associated receptor changes: high and low [Ca ] assay
To investigate the possible role of Ca in receptor regulation,
the two and twelve day experiments were repeated with the receptor assays
performed under low or high [Ca++]. The results for the two day
experiments are shown in Figure 5.3. No consistent change in receptor
affinity was observed (Table 5.1). For each dietary/drug regimen the same
++ ++values of receptor density were obtained in high [Ca ] and low [Ca ] as 
for control animals in the same [Ca++] assay. Considering the results 
presented in Section 4.12, this, would suggest that two days after 
alteration of plasma angiotensin II concentration there is no net change 
in receptor number but that a proportion of the receptors have been masked 
or inactivated through a mechanism which is reversed by high [Ca ].
With the normal [Ca++] assay, receptor density appeared 
significantly higher after twelve days of converting enzyme blockade and 
significantly lower after twelve days of sodium loading (Figure 5.2).
However, for both groups the same values of receptor density were obtained
++ "H"in high [Ca ] and low [Ca ] as for control animals in the same [Ca ]
assay (Figure 5.4). This suggests that more prolonged suppression of
plasma angiotensin II concentration also has no effect on net receptor
number and that the factor responsible for the differing effects of
converting enzyme blockade and sodium loading acts by modulating the
putative Ca++-antagonised receptor-masking mechanism.
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plasma angiotensin II concentration: high/low [Ca ] assay, 
2 day protocols
The 2 day sodium loading, sodium depletion and captopril administration 
experiments were repeated with the receptor assays performed in low and 
high [Ca++]. Results are presented as point estimate ± standard error for 
3 or more experiments (actual values are given in Table 5.1). The values 
obtained in normal [Ca++] are also shown (from Figure 5.2). The hatched 
regions denote the receptor density observed for normal animals in low, 
normal and high [Ca++] assay.
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plasma angiotensin II concentration: high/low [Ca ] assay, 
12 day protocols
The 12 day sodium loading, sodium depletion and captopril administration 
experiments were repeated with the receptor assays performed in low and 
high [Ca++]. Results are presented as point estimate ± standard error for 
3 or more experiments (actual values are given in Table 5.1). The values 
obtained in normal [Ca++] are also shown (from Figure 5.2). The hatched 
regions denote the receptor density observed for normal animals in low, 
normal and high [Ca++] assay.
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Table 5.1
Effect of dietary & drug regimens on mesenteric artery receptor binding
125constants for I-angiotensm II
GROUP RECEPTOR 
DENSITY 
(fmol/mg) 
a
FORWARD RATE 
CONSTANT 
log [M-l.s“l]
,A_
REVERSE RATE 
CONSTANT 
log [s_1]
N
Captopril
acute
r
99.7 ± 3.3
(
5.794 ± 0.028
r
-4.017 ± 0.144 3
2 days 110.8 ± 2.7 6.113 ± 0.110 -3.767 ± 0.127 3
5 days 118.0 ± 7.1 5.706 ± 0.033* -3.910 ± 0.079 3
12 days 118.0 ± 6.0* 5.810 ± 0.069 -3.948 ± 0.167 5
2 days low [Ca++] 39.9 ± 6.0 5.431 ± 0.053* -3.824 ± 0.103 3
2 days high [Ca++] 150.0 ± 8.0 5.873 ± 0.000 -4.294 ± 0.002 4
12 days low [Ca++] 47.0 ± 5.6 5.571 ± 0.133 -3.512 ± 0.320 3
12 days high [Ca++] 151.7 ± 4.9 6.014 ± 0.020 -4.207 ± 0.007 3
High salt
2 days 99.5 ± 4.1 5.696 ± 0.479 -4.171 ± 0.111 3
5 days 90.1 ± 7.0 5.809 ± 0.025 -3.783 ± 0.034* 5
5 days (no saline) 85.6 ± 6.2* 5.857 ± 0.028 -4.021 ± 0.038 3
12 days 77.5 ± 3.7* 5.981 ± 0.175 -3.603 ± 0.314 5
12 days (no saline) 76.0 ± 4.1* 5.830 ± 0.142 -4.059 ± 0.148 3
2 days low [Ca++] 47.0 ± 3.7 5.586 ± 0.119 -3.511 ± 0.333 3
2 days high [Ca++] 151.5 ± 5.0 5.874 ± 0.215 -4.056 ± 0.276 3
12 days low [Ca++3 47.8 ± 5.0 5.805 ± 0.027 -4.066 ± 0.030 4
12 days high [Ca++] 146.1 ± 6.0 5.777 ± 0.085* -3.656 ± 0.310 4
NORMAL low [Ca++] 49.9 ± 4.0 5.802 ± 0.136 -3.795 ± 0.013 5
NORMAL 102.2 ± 4.2 5.897 ± 0.052 -4.208 ± 0.165 5
NORMAL high [Ca++] 156.2 ± 4.6 6.023 ± 0.080 -3.910 ± 0.310 5
Low salt
2 days 88.0 ± 3.9* 5.915 ± 0.419 -3.459 ± 0.453 3
5 days 70.3 ± 4.1* 5.742 ± 0.092 -4.099 ± 0.257 3
12 days 59.8 ± 3.2* 5.833 ± 0.025 -3.922 ± 0.032 3
Low salt + diuretic
2 days 76.0 ± 3.3* 5.808 ± 0.139 -4.132 ± 0.632 3
5 days 53.8 ± 2.9* 5.861 ± 0.052 -3.989 ± 0.066 3
12 days 44.1 ± 4.8* 5.687 ±.0.086* -4.482 ± 0.710 4
2 days low [Ca++] 39.9 ± 5.4 5.397 ± 1.050 -3.991 ± 0.243 3
2 days high [Ca++] 150.1 ± 8.0 5.913 ± 0.061 -3.961 ± 0.257 3
12 days low [Ca++] 26.7 ± 1.9* 5.841 ± 0.035 -4.410 ± 0.034* 4
12 days high [Ca++] 49.0 ± 6.9* 5.843 ± 0.090 -4.036 ± 0.372 5
Results obtained using the receptor assay, given as point estimate ± 
standard error. The number of experiments is given (N), with 12 rats used 
for each experiment. In some of the sodium loading experiments, the salt 
was administered in the food only (Table 2.1); these are indicated (no 
saline). A parameter estimate differing significantly from that for 
control animals obtained in the same [Ca++] assay is indicated (*).
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In contrast, prolonged elevation of plasma angiotensin II
concentration had a quite different effect; the increase in receptor
++ ++number usually observed between normal [Ca ] and high [Ca ] was lost and 
the value obtained in low [Ca++] was significantly below that for all 
other groups (Figure 5.4). This may correspond to an actual loss of 
receptors. As before, no consistent change in receptor affinity was noted 
(Table 5.1).
5.6 Angiotensin II metabolism
Based on organ perfusion experiments, Leary & Ledingham (1970) 
proposed that alteration of sodium balance affects the rate of angiotensin 
II metabolism and that this may contribute to the observed changes in 
pressor sensitivity to the peptide. Since the rate of tracer angiotensin 
II degradation by the arterial membrane fraction was routinely measured as 
part of the receptor assay, this hypothesis could easily be tested. Table
5.2 shows the results for regression of the apparent tracer decay rate 
constant against time (duration of dietary/drug protocol) and against 
membrane protein concentration. There was no relationship with time but a 
highly significant and very similar relationship with membrane protein 
concentration was observed for all groups. The results therefore do not 
lend any support for this hypothesis. The relationship between membrane
protein concentration and tracer decay rate was not different between
++ ++ normal [Ca ] and high [Ca ] assays but tracer degradation rate was
markedly reduced by removal of divalent cations (Table 5.2 & Figure 5.5).
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Table 5.2
Effect of dietary & drug regimens on angiotensin II metabolism by the
arterial membrane fraction
GROUP COEFFICIENT
Captopril [PROTEIN]
TIME
0.00624 ± 0.00118 
■0.02360 ± 0.04027
p=0.0005 
p= NS 
r^=0.9043
High salt [PROTEIN]
TIME
0.00479 ± 0.00065 
0.02999 ± 0.02736
p<0.0001 
p= NS 
r2=0.9530
NORMAL [PROTEIN] 0.00561 ± 0.00030 p<0.0001
r =^0.9133
Low salt [PROTEIN]
TIME
0.00607 ± 0.00101 
-0.02200 ± 0.04750
p=0.0004 
p= NS 
r2=0.9334
Low salt + diuretic [PROTEIN]
TIME
0.00367 ± 0.00077 
0.04786 ± 0.03389
p=0.0007 
p= NS 
r^=0.9164
All experiments 
high [Ca++] assay [PROTEIN]
All experiments
normal [Ca++] assay [PROTEIN]
All experiments 
low [Ca++] assay [PROTEIN]
0.00499 ± 0.00023
0.00556 ± 0.00021
p= NS
p=0.0212
0.00305 ± 0.00023
The upper part of the table gives the results of no-constant multivariate 
regression of 125i_angi0tensin n  apparent degradation rate (k^ g, measured 
as part of the receptor assay) in normal [Ca++] assay against duration of 
dietary/drug regimen (TIME) and arterial membrane protein concentration 
([PROTEIN]). The p values derived from t-statistics show that for each 
group was strongly related to protein concentration and did not change 
with time. Comparison of the [PROTEIN] coefficients (given as estimate ± 
standard error) was made by calculating the ratio k^/protein 
concentration for each experiment and then using unpaired t-tests. There 
was no significant difference (p>0.05, NS) between the control and any of 
the treated groups. In the lower part of the table, the same method was 
used to compare values of k^ in high, normal and low [Ca++] assays. As 
shown, tracer decay rate was significantly reduced in low [Ca++] but did 
not differ between normal and high [Ca++].
(r^ ; coefficient of determination).
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125Figure 5.5 Relationship between I-angiotensin II degradation rate
and arterial membrane protein concentration
The figure shows the linear relationship between arterial membrane protein 
concentration and 125I-angiotensin II degradation rate (determined by 
filtrate immunoassay). Each point represents one receptor assay. The 
regression lines shown are based on the statistical analysis described in 
Table 5.2.
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CHAPTER 6 
GENERAL DISCUSSION
6.1 Introduction
At the commencement of this study, only two reports appeared in 
the literature on angiotensin receptors in resistance vessels (Gunther et 
al, 1980a,b), with most accounts based on work with model tissues such as 
aortic and uterine smooth muscle. The aims of the project were to confirm 
the observations made by these authors and to develop an assay for the 
mesenteric artery angiotensin receptor which could be used to study the 
physiologic regulation of these receptors. The findings of the present 
study are largely in agreement with others published on this topic, 
although certain important differences, most probably of methodological 
origin, have been noted. These have been mentioned in Chapter 4 and are 
discussed more fully below along with other aspects of the results. To 
avoid unnecessary repetition, the discussion will make extensive use of 
the review of the literature presented in Chapter 1.
In the discussion on the role of divalent cations in receptor 
regulation, the phrase "apparent receptor density" is used when referring 
to the results presented herein since the receptor density determined by 
radioligand receptor assay varies with the divalent cation concentration 
in the assay incubation medium. This phrase is not used when referring to 
previous reports on angiotensin receptor regulation, since each of these 
studies was performed with a fixed composition assay medium (see Table 4.4 
for those used for the mesenteric artery receptor). However, it seems 
likely that in some cases (mostly those where a smooth muscle tissue has 
been used) the observed receptor densities will be (in part) a function of 
the assay medium composition.
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6.2 General aspects of the vascular angiotensin receptor
125The binding sites for I-angiotensin II identified in this study
display characteristics expected of a physiological receptor for
angiotensin II. The kinetic constants should allow rapid interaction, and
thus rapid response, with angiotensin II at normal plasma concentrations,
and the observed concentration of binding sites (100 fmol/mg of membrane
4protein) would correspond to a receptor density of the order of 10
6sites/cell, assuming 10 cells/lOOmg wet weight of tissue and 50% recovery 
in the preparation of the membrane fraction. A similar value has been 
reported for rat mesenteric artery smooth muscle cells in culture (Gunther 
et al, 1982). The binding sites also discriminate between angiotensin- 
related peptides in the expected manner. The 4-fold difference in affinity 
for angiotensins II & III, the lack of binding by angiotensin I and the 
very low affinity of the C-terminal hexa- and pentapeptides exactly 
parallels the pressor activities of these peptides (Helmer, 1955; Bumpus 
et al, 1961; Campbell et al, 1977a; Schwyzer, 1963; Carey et al, 1978). 
The binding constants were similar at 22°C and 37°C, and while it may be 
an oversimplification to derive thermodynamic constants with data at only 
two temperatures (Table 4.3), the values of AH0' (-22kJ/mol) and AS0' (-58 
J/mol/°) seem appropriate for the interaction of a small random coil 
peptide with its receptor. The half-life of the hormone-receptor complex 
is long (6900 seconds) which suggests that dissociation of the complex is 
not the in vivo process which terminates the hormonal response (see below, 
Cation effects and receptor regulation).
It has been reported that the angiotensin II competitive
1 8  1 8  antagonists (e.g. sar thr and sar ala [saralasin] peptides) display
equal or greater affinity than the native peptide for the smooth muscle
receptor (Devynck & Meyer, 1976; Gunther et al, 1980a,1982; Aguilera &
Catt, 1981). However, as shown in Section 4.9 the sarcosine^ peptides were
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considerably more resistant to degradation than angiotensin II. The 
sarcosine1 substitution greatly increases the half-life of the peptide in 
the circulation (Pettinger et al, 1975). When this was taken into account, 
the antagonists were found to display an appreciably lower affinity for 
the receptor than angiotensin II (Figure 4.7 and Table 4.5). In the rat 
(and other species) plasma angiotensin II concentration may reach, under 
extreme circumstances, InM (Boucher et al, 1977). Pettinger et al (1975) 
found that plasma saralasin concentrations of 30 and 300nM produced 10 and 
100-fold shifts respectively in the angiotensin II pressor dose-response 
relationship in this species. Thus pharmacological evidence agrees with
o
the observed lower affinity for the antagonists. The ile peptide has both 
the highest affinity and the highest degree of agonist activity of all 
angiotensin antagonists tested to date (Davis et al, 1974). As shown in 
Table 4.5, this peptide showed a 10-fold higher affinity than the other 
antagonists.
Previous bioassay experiments have shown that tyrosyl mono- 
iodinated angiotensin II retains only a proportion (25-70%) of the pressor 
activity of the native peptide (Lin et al, 1970; Kurchbart et al, 1971; 
Papadimitriou & Worcel, 1974). However, in vascular smooth muscle (Gunther 
et al, 1980a; Aguilera & Catt, 1981; present study), adrenal cortex 
(Glossman et al, 1974c); brain (Bennet & Snyder, 1976), heart (Wright et 
al, 1983; Baker et al, 1984), kidney (Brown & Douglas, 1982), liver 
(Sernia et al, 1985) and platelets (Moore & Williams, 1982) no 
discrimination between labelled and unlabelled peptides is apparent. As 
discussed in Section 4.11, artefactual results may have been obtained in
the earlier experiments through impurity of the radiolabelled peptide.
125Repetition of the bioassay experiments (Section 4.11) using I- 
angiotensin II of high purity showed this peptide to retain full pressor 
activity, thus removing any discrepancy. It seems likely that full
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activity is also retained in the other angiotensin target tissues noted 
above.
6.3 Possible nature of the low-affinity component of binding
It is unlikely that the second class of binding sites is involved 
in mediating response to angiotensin II as their low affinity (K^ =50nM) 
would probably not permit interaction with angiotensin II at normal plasma 
concentrations. It is also unlikely that these sites represent binding of 
tracer to a peptidase enzyme as tracer degradation was not affected by the 
presence of lOuM unlabelled angiotensin II which blocks high- and 
low-affinity binding. The low capacity (700 fmol/mg protein) is not 
consistent with uptake of radioactivity into membrane vesicles. Further­
more, chromatographic analysis of bound radioactivity after incubation 
125with 20nM I-angiotensin II, conditions in which about 20% of the
specifically bound radioactivity is associated with the low-affinity site,
125showed it to be composed entirely of I-angiotensin II and (to a lesser 
125extent) I-angiotensin III (Section 4.3a). Therefore the low-affinity 
site appears to discriminate between physiologically active angiotensin 
peptides and the inactive metabolites produced during incubation.
The affinity of this class of binding sites is similar to that of 
the angiotensin binding sites seen in aortic smooth muscle, which show 
various characteristics of a physiological receptor for angiotensin II and 
mediate contraction of this muscle tissue in response to the peptide. Thus 
the second class of sites may be related to or derived from the active 
(high-affinity) receptor, possibly through receptor inactivation or lack 
of activation to the high-affinity form. For methodological reasons, it is 
difficult to compare results from different studies, but there appears to 
be a spectrum of angiotensin receptor affinity, with reported values of
10-50nM for aortic smooth muscle, 2-1OnM for uterine muscle and 0.1-lnM 
for rat mesenteric artery tissue. Aguilera & Catt (1981) report identical
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binding characteristics for rat mesenteric artery and urinary bladder 
muscle. Factors associated with the differentiation of the tissue may 
therefore exert effects on the receptors.
In the presence of GTP or a GTP analogue many receptors display an
altered affinity for agonists due to interaction of the agonist-receptor
complex with a GTP-binding receptor-effector coupling protein (Catt et al,
1979; Gilman, 1984; Lefkowitz et al, 1984; Berridge & Irvine, 1984). The
large difference in affinity of the two classes of sites in mesenteric
artery smooth muscle and the ratio of binding site concentrations suggests
that such a process does not account for the heterogeneity of angiotensin
II binding sites in this tissue. As described in Section 4.12, maximal 
125inhibition of I-angiotensin II binding by Gpp(NH)p was due to a 10-fold 
reduction in affinity with relatively little change in receptor density. 
Had Gpp(NH)p caused an interconversion of binding sites, this would have 
been apparent as a change in the concentration of high-affinity sites 
under the assay conditions employed. GTP and its analogues are inhibitory 
against the aortic angiotensin receptor (Devynck & Meyer, 1976). Under no 
conditions was there any indication of interconversion of high- and 
low-affinity binding sites.
Only occasionally has a similar low-affinity binding site for 
angiotensin II been observed, probably due to the use of a more narrow 
range of tracer concentrations in saturation binding experiments (see 
below, Methodological aspects). Glossman et al (1974c) observed a second 
class of angiotensin II binding sites in adrenal cortex with a of 30nM. 
However, in various tissues, two classes of binding sites with values 
differing approximately ten-fold have been observed, and it has been 
claimed that the receptor subtypes in liver are functionally distinct 
(Gunther, 1984).
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6.4 Methodological aspects
Degradation of peptide ligands in binding studies is commonly 
encountered and seriously affects the calculation of binding constants for 
the receptor under study (Ketelslegers et al, 1975). These authors 
observed that ligand and/or receptor degradation predominantly affects the 
estimate of affinity and that the effect is more apparent under pseudo­
equilibrium conditions than in kinetic experiments. Computer simulations 
(not shown) carried out as part of the present study support these 
findings, as do the experimental results. For this reason, short 
incubations were used to minimise the effect of changes in tracer
degradation rate when comparing the effect of cations and proteinase 
125inhibitors on I-angiotensin II binding.
It is standard practice for incubations to be performed at reduced 
temperature (usually 22°C) to limit ligand destruction. However, for small 
peptides such as angiotensin II which are particularly susceptible to 
proteolysis due to their lack of tertiary structure, this may not be 
effective. In these circumstances proteinase inhibitors are often used 
(see Table 4.4 for those used with the mesenteric artery preparation). It 
is also usual for such inhibitors to be added without examination of their 
effects on the receptor. As shown in Table 4.1, some were inhibitory 
against the receptor and it was not possible to effectively prevent ligand 
degradation without adversely affecting binding. In many instances these 
inhibitors only partially prevent ligand destruction; unrecognised tracer 
degradation would account for the main differences between this study and 
those listed in Table 4.4; these are the affinity of angiotensin II for 
the receptor and the relative affinities of angiotensin II and the sar^ 
antagonists (Note that for the mesenteric artery receptor, reported 
values range from 0.1-lnM while values of receptor concentration vary only 
from 50-100 fmol/mg protein; as described above, ligand degradation
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affects mainly the estimate of affinity). The influence of calcium on 
receptor density described in Sections 4.12 and 5.5 emphasises the 
potential importance of the effect of proteinase inhibitors on the 
receptor; clearly, had chelating agents been used then these observations 
could not have been made.
As mentioned previously, saturation binding curves constructed 
using a limited range of tracer concentrations may fail to reveal a low- 
affinity component of binding. In the present study, linear Scatchard 
plots (not shown) could be obtained under such conditions, with the 
values derived from them (-1/slope) lying in the range 0.5-lnM, similar to 
the values obtained by Gunther et al (1980a). Usually 30-60% of the tracer 
was destroyed during incubation, resulting in overestimation of the by 
a factor of 5-10. Where a second low-affinity class of binding sites is 
present, limited saturation binding curves may also yield incorrect values 
for receptor density since the Scatchard plot, although linear, still 
contains a low-affinity component. For further discussion on these 
methodological aspects see Klotz (1982) and Mendel & Mendel (1985).
For technical reasons it was not possible to fully saturate the 
low-affinity sites in the routine receptor assay. Account of the low- 
affinity component of binding was taken by assuming it to be linear with 
tracer concentration (over the range employed) and subtracting this linear 
component in the analysis of the binding data. This approach required that 
the concentration range used saturated the high-affinity sites (2-4nM) and 
allowed adequate definition of the linear low-affinity component. The use 
of tracer concentrations of (approximately) 0.05-10nM satisfied this 
requirement (see Figure 4.6). In the analysis of the assay data, curve 
fitting to at least three replicate experimental curves was performed 
simultaneously, under the assumption that the parameters relating to the 
high-affinity site were common to all of the data. The constraints which
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this imposed on the analysis together with the content of the experimental 
data permitted good resolution of the high-affinity component of binding, 
as is evident from the reproducibility of the results (see Tables 4.3 and
5.1).
Attempts were made to determine if the physiological manipulations 
described in Chapter 5 had any effect on the low-affinity binding sites. 
However, even when the affinity of these sites was assumed constant and 
the receptor concentrations estimated by applying the multiple receptor 
density method (Section 3.2b) to large sets of data, the standard errors 
of the estimates were large and no conclusions could be made from the 
results.
Although computationally demanding, direct curve-fitting techniques 
represent the optimum method for analysis of complex ligand binding 
systems such as that described. As noted above, correction for ligand 
and/or receptor degradation is preferable to the use of proteinase 
inhibitors which may have a significant adverse effect on the receptor(s), 
and the flexibility of nonlinear regression will allow quantitative 
description of other factors such as heterogeneity of binding sites of 
co-operative effects which may invalidate conventional methods of 
analysis. Even where linearizing transformations are technically 
applicable, simple curve-fitting procedures may be more suitable as 
transformation can distort the experimental data (Duggleby, 1980; Thakur 
et al, 1980). An advantage of the methods described is that kinetic 
constants may be readily obtained as part of a receptor assay. This is an 
important feature in respect of hormone-receptor systems, where in vivo a 
dynamic rather than true chemical equilibrium will exist, and equilibrium 
constants may be inappropriate for a full description of the system.
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6.5 Cation effects and receptor regulation
In many tissues, cations have been found to influence the binding 
of angiotensin II to its receptor. The nature of this effect is not 
fixed, but varies between tissues. This is most apparent when comparing 
adrenal cortex and smooth muscle. In adrenal cortex, monovalent cations 
(especially sodium) greatly increase binding through an increase in 
affinity, whereas divalent cations have little effect (Glossman et al, 
1974a,b; Douglas et al, 1978a; Douglas et al, 1982). In mesenteric artery 
(Gunther et al, 1980a; Wright et al, 1982), uterine (Douglas et al, 1982) 
and cardiac (Wright et al, 1983; Baker et al, 1984) smooth muscle divalent 
cations (Ca++, Mg++) markedly enhance binding whereas sodium and other 
monovalent cations show only a modest effect (inhibitory in heart). With 
the exception of the study by Wright et al (1982), an increase in receptor 
number was observed in all cases. Similar findings have been reported for 
liver (Campanile et al, 1982; Gunther, 1984). In renal tissues both sodium 
and divalent cations exert an appreciable effect on angiotensin II 
binding, sodium increasing receptor affinity and divalent cations 
increasing receptor number (Brown & Douglas, 1982; Douglas et al, 1982). 
In brain, sodium causes a maximal 25-fold increase in affinity (Bennett & 
Snyder, 1980a) but probably due to tracer angiotensin II degradation the 
effect of divalent cations has not been investigated. In all cases, sodium 
was active over the range 0-150mM and divalent cations over the range 
0-10mM.
The results shown in Section 4.12 are in agreement with previous 
reports for the smooth muscle angiotensin receptor. Sodium caused a slight 
increase in binding, even when maximal stimulation by calcium had been 
achieved, but the biphasic effect of sodium (also noted by Wright et al, 
1982) was more marked in the presence of calcium. This, together with 
the observations described above, suggests that sodium and calcium act via
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different mechanisms, but at concentrations greater than lOOmM sodium 
interferes with the action of calcium. This may explain the small
inhibitory effect of sodium seen in cardiac smooth muscle.
In the study by Bennett & Snyder (1980a), a differential effect of 
sodium on angiotensin II and N-terminal sarcosine substituted peptides was 
observed, sodium increasing receptor affinity only for the native peptide 
(aspartic acid at the N-terminus). A similar but less marked effect was
noted for adrenal cortex, and no such effect was evident in uterine smooth
muscle. To an extent, this resembles the differential effect of sodium 
on agonist and antagonist binding which has been reported for a variety of 
hormone-receptor systems [opiate (Pert & Snyder 1974; Childers & Snyder, 
1980), cardiac muscarinic (Rosenberger et al, 1980), alpha- and beta- 
adrenergic (U'Prichard & Snyder, 1978; Yamamura & Rodbell, 1976) and 
histamine (Chang & Snyder, 1980)]. However, Bennett & Snyder (1980a) 
found no correlation between the influence of sodium on the binding of 
angiotensin II analogues and agonistic or antagonistic properties of the 
peptides. In agreement with the findings of these authors, displacement of 
"^I-angiotensin II by sar'*’ thr^  angiotensin II from the mesenteric artery 
receptor in the absence and presence of sodium (150mM) yielded identical 
results (not shown).
Divalent cations also exert a differential effect on agonist and 
antagonist binding in several systems [opiate (Blume, 1978; Childers & 
Snyder, 1980), alpha- and beta-adrenergic (Pasternak et al, 1975; Tsai & 
Lefkowitz, 1978; U'Prichard & Snyder, 1978; Williams et al, 1978b), 
dopaminergic (Usdin et al, 1980) and histamine (Chang & Snyder, 1980)]. 
In all cases, divalent cations increased affinity predominantly for 
agonists, and in some cases opposed the effects of GTP and sodium. In the 
studies on the effect of sodium quoted above, GTP produced a similar 
effect, and the results of Chang & Snyder (1980) indicate that sodium
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enhances the discriminatory effect of GTP on agonist and antagonist 
binding. It has been suggested (Childers & Snyder, 1980) that the effect 
of divalent cations is due to stimulation of GTP hydrolysis. In studies 
where several different divalent cations have been used, Mn++ was usually 
much more potent than Ca++ (Chang & Snyder, 1980; Childers & Snyder, 1980; 
Usdin et al, 1980).
With the exception of studies on angiotensin II binding, there are 
few accounts describing an effect of cations on receptor number. In 
addition to the effect of mono- and divalent cations on dopamine receptor 
affinity described above, sodium and manganese also apparently increased 
receptor density (Usdin et al, 1980). The number of binding sites for di- 
hydropyridine calcium channel antagonists in brain (but not heart) 
membranes varies with the incubation medium calcium concentation over the 
range 0-lmM (Gould et al, 1982), but it seems unlikely that there is any 
connection between this effect and the influence of divalent cations oh 
angiotensin II binding. There is no evidence for a direct link between the 
angiotensin receptor and voltage-dependent Ca++ channels (Section 1.9) and 
dihydropyridine drugs do not influence angiotensin II binding in 
mesenteric artery smooth muscle cell membranes (results not shown).
It is known that calcium can alter the physicochemical state of 
lipid bilayers (Houslay & Stanley, 1982) and it might therefore indirectly 
affect the angiotensin receptor. However, in that case an influence of 
divalent cations on receptor density should be a more general phenomenon. 
The shifts in the [Ca++]-apparent receptor density relationship described 
in Chapter 5 are also not consistent with an effect of Ca++ on membrane 
structure. It is well established that the effects of changes in sodium 
balance on target tissue sensitivity to angiotensin II are selective for 
this peptide (Strewler et al, 1972; Oliver & Cannon, 1978; Aguilera & 
Catt, 1981). Although it has been reported that angiotensin II can act as
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an ionophore for divalent cations (Degani & Lenkinski, 1980), the 
magnitude of this effect was small and the conditions used to demonstrate 
it so extreme (millimolar concentrations of peptide at 50-60°C) that it 
probably has no physiological relevance. For reasons given below, the 
formation of an angiotensin II-Ca++ complex does not appear to be involved 
in the effect of calcium.
As described in Section 1.2e, tachyphylaxis to angiotensin appears 
to be a function of the N-terminus of the octapeptide, and to involve 
calcium and possibly a receptor-related factor. The results shown in Table
4.6 indicate that guanine nucleotides and calcium act on the receptor via 
different mechanisms, calcium still influencing apparent receptor number 
even when maximal inhibition of binding by Gpp(NH)p had been achieved. As 
discussed previously, guanine nucleotides probably allow the hormone- 
receptor complex to interact with a coupling protein, and through this 
mechanism affect predominantly agonist binding. This effect might 
therefore be a function of the C-terminus of the peptide (angiotensin 
antagonists being C-terminal substituted). This would be consistent with 
two functional domains in the peptide, the effect of calcium being 
associated with the N-terminus.
Paiva et al (1977) have suggested that tachyphylaxis results from 
tight binding of angiotensin II to its receptor, with recovery due to 
displacement of the peptide by calcium. Since the effect of calcium is 
reversible (Figure 4.11), this proposal does not appear correct. It should 
be noted that these experiments were performed at reduced temperature 
(10°C) to limit receptor degradation, and the primary object was to verify 
that the tissue processing procedures did not affect the in vivo state of 
the receptors with respect to calcium. Preincubation of the arterial 
membrane fraction at higher temperature (22°C or 37°C, 10-20 minutes) in 
Tris buffer before addition of tracer angiotensin II and calcium markedly
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reduced the stimulatory effect of calcium without affecting basal 
angiotensin II binding (results not shown). This rules out the possibility 
that the effect of calcium is due to the formation of an angiotensin
II-Ca++ complex, and is also not consistent with "prior occupancy" of the 
receptors by endogenous peptide.
The alterations in the relationship between [Ca++] and apparent 
receptor density described in Chapter 5 imply the existence of two 
subgroups of receptors which can exist in a masked (inactive) state and 
which differ in sensitivity to unmasking by calcium. While it is possible 
that the angiotensin II binding seen in low [Ca++] assay is due to failure 
of the chelating agents to remove all divalent cations, this is unlikely 
and suggests a third receptor subgroup which is unaffected by calcium. A 
speculative scheme for the regulation of the receptors is shown in Figure 
6.1. It is assumed that under agonist occupancy, a proportion of the 
receptors (R) form an inactive (unable to bind ligand) complex (RFT), 
where F^ is the tachyphylaxis factor. The differing extent to which 
tissues become tachyphylactic to angiotensin II would therefore reflect 
the activity of FT. This complex dissociates in the presence of calcium, 
liberating active (able to bind ligand) receptors. Under prolonged agonist 
occupancy, the receptors may be subject to a covalent modification (R'), 
with the r'ft complex less sensitive to calcium (by analogy, glycogen 
phosphorylase kinase exists in two forms, the phosphorylated form being 
more sensitive to activation by calcium). The shifts in the [Ca++]- 
apparent receptor density relationship would therefore correspond to the 
interconversion of R and R '. Regulation of the B-adrenergic receptor may 
involve phosphorylation of the receptor (Sibley & Lefkowitz, 1985). By 
analogy with the GTP-binding receptor-effector coupling proteins, the 
enzymatic activity for the covalent modification of R might reside in FT» 
Prolonged agonist-occupancy may also result in a loss of receptors by an
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FT-Ca"+R R'+FT-Ca"
Ca -  j
R R-Ft --------- - R i f
Ca" Ca"
Figure 6.1 Prclosed mechanism of vascular angiotensin receptor
regulation
Under agonist occupancy, the receptor (R) forms an inactive complex (RFT) 
with the tachyphylaxis factor (FT). This complex dissociates in the 
presence of Ca liberating active receptors. In a slower process the 
receptor is subject to a modification (R') with the R'Ft complex less 
sensitive to dissociation by Ca . This modification m y  precede actual 
loss of receptors by an internalisation/degradation process (not shown).
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internalisation/degradation process which could be related to the covalent 
modification of the receptor (Catt et al, 1979; Cuatrecasas & King, 1981; 
Lefkowitz et al, 1984; Sibley & Lefkowitz, 1985). If were spared in 
this process, the effect of prolonged agonist action would then be a 
reduction in the total number of receptors (seen in high [Ca++] assay) and 
a reduction in the number of calcium-insensitive receptors (seen in low 
[Ca++] assay) in addition to an alteration in the relative concentrations 
of R and R'.
Calcium may itself regulate the receptors, or may act as a 
cofactor in the action of FT. The plasma free calcium concentration 
changes very little, but is in the range which affects the receptor. 
Manipulation of the extracellular [Ca++] does alter the extent to which 
tachyphylaxis occurs (Ackerly et al, 1977a; Paiva et al, 1977) but could 
alter Ca++ availibility within the cell. Calcium channel blockade may 
influence the tachyphylactic mechanism (Ackerly et al, 1977a; see Section 
1.2e) suggesting an intracellular site of action. The intracellular 
calcium concentration is normally too low to modify the receptor status, 
but since angiotensin II action can result in measurable efflux of calcium 
from the cell (presumably released from the endoplasmic reticulum in the 
vicinity of the receptor under the action of inositol trisphosphate, see 
Section 1.9) the receptor may experience a high [Ca++] during this 
process. The regulatory effect of calcium might therefore be connected 
with angiotensin action. As noted previously, the half-life of the 
angiotensin-receptor complex is long and thus dissociation of the peptide 
may not be the terminator of the hormonal response. Instead, formation of 
the RFt complex may end the stimulus, with reactivation of the receptor 
depending on the availability of calcium. Reduced availability of calcium 
would accelerate the formation of R', and might therefore affect 
predominantly the onset of tachyphylaxis. This would agree with the
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findings of Paiva et al (1977).
In the above scheme, calcium acts on a receptor-related factor 
rather than the receptor itself, and the proposed covalent modification 
affects the receptor-FT interaction rather than the receptor-ligand 
interaction. Consequently calcium would not alter receptor affinity for 
angiotensin II and would have no effect on angiotensin II binding in 
tissues which lack FT (such as adrenal cortex, and aortic smooth muscle 
which does not exhibit tachyphylaxis to angiotensin II).
While it is suggested that the receptor undergoes a covalent 
alteration, it is equally possible that the activity of FT is modified. 
The differing effects of sodium loading and converting enzyme blockade on 
receptor status (Chapter 5) may be due to another hormone which modulates 
the activity of F^,. A number of studies have indicated that factors in 
addition to plasma angiotensin II concentration determine vascular, 
adrenocortical and other target organ sensitivities to the peptide 
(Dawson-Hughes et al, 1981; Olsen & Meydrech, 1985; see also Section 
1.2d). Insulin has been shown to modulate angiotensin receptor density in 
renal glomeruli (Ballerman et al, 1984), and may have a similar effect in 
vascular tissues (Turlapaty et al, 1980). There is no indication that 
plasma insulin concentration would change with manipulation of sodium 
balance. It is not known if glucocorticoids have any effect on angiotensin 
receptor status, but plasma corticosterone concentration is not affected 
by alteration of sodium intake (Schiebinger & Kontrimus, 1985).
As described in Section 5.3, plasma aldosterone concentration was
consistently higher in the captopril-treated rats than in the sodium
loaded animals but only significantly so after 12 days. If aldosterone
does modulate vascular angiotensin receptor density as suggested by
Schiffrin et al (1983c), then the slow fall in apparent receptor density 
++(normal [Ca ] assay) induced by sodium loading could be due to the
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greater suppression of plasma aldosterone concentration by this treatment.
Atrial natriuretic peptide (ANP) antagonises the action of a 
number of vasoconstrictors, especially angiotensin II (Kleinert et al, 
1984) . At present it is not clear if plasma ANP levels are altered by 
manipulation of sodium balance in the rat, although an increase in plasma 
ANP concentration with sodium loading would be expected in view of the 
natriuretic, vasorelaxant and anti-steroidogenic activities of this 
peptide (see Schiffrin et al, 1985 for references). Specific high-affinity 
receptors for ANP have been identified in membrane fractions from rat 
mesenteric artery and adrenal cortex (Schiffrin et al, 1985). ANP appears 
to be an endogenous antagonist of the renin-angiotensin system, and might 
act (in part) by modulating angiotensin receptor status.
It has long been established that sodium loading causes an 
increase in pressor sensitivity to infusion of angiotensin II, but the 
results of this study suggest a reduction in vascular smooth muscle 
responsiveness to the peptide. It is possible that the increased 
sensitivity to infusion of angiotensin II seen with sodium loading is due 
to hemodynamic factors; while the blunted smooth muscle response to 
angiotensin II can be demonstrated in vitro with tissue taken from animals 
after activation of the renin-angiotensin system (Strewler et al, 1972; 
Sybertz & Peach, 1980) the corresponding experiment with tissue from 
sodium loaded animals does not appear to be reported in the literature. As 
discussed above, a second hormone may regulate receptor status. Since 
sodium loading caused a reduction only in the apparent (normal [Ca++] 
assay) number of receptors, it is possible that infusion of angiotensin II 
under these circumstances would rapidly redress the balance of hormonal 
influences on the receptors. Conceivably, sodium loading at a lower level 
than used in the present study could suppress plasma angiotensin II 
concentration without markedly affecting other hormonal influences on the
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receptors, and would therefore produce the same effect as captopril 
administration. This would explain the up-regulation of the mesenteric 
artery receptors with sodium loading (0.3% NaCl diet) observed by Aguilera 
SrCatt (1981).
There are several parallels between angiotensin receptor 
regulation in smooth muscle and adrenal cortex. Elevation of plasma 
angiotensin II concentration results in a blunted smooth muscle response 
to the peptide but potentiates adrenocortical sensitivity. In both 
tissues, receptor regulation appears to involve two stages; in smooth 
muscle there is an initial masking/unmasking of receptors followed by an 
actual change in receptor number, while in adrenal cortex there is an 
initial alteration of receptor affinity followed by a change in receptor 
number with normalisation of affinity. As discussed previously, divalent 
cations affect the vascular receptor, acting through a mechanism which 
seems to involve the N-terminus of angiotensin II and which may be 
connected with angiotensin tachyphylaxis, while sodium influences the 
affinity of the adrenocortical receptor, also through a mechanism which 
involves the N-terminus of the peptide. In other respects (selectivity for 
angiotensin peptides, effect of guanine nucleotides and physicochemical 
characteristics) the receptors are very similar (Sections 1.2 & 1.3). In 
adrenal cortex there might be a counterpart of the smooth muscle 
tachyphylaxis factor postulated above which regulates steroidogenic 
sensitivity to angiotensin II. Since an influence of monovalent and/or 
divalent cations on the angiotensin receptor-ligand interaction has been 
described for most tissues studied to date, such receptor-related factors 
may prove to be more generally involved in the regulation of target organ 
sensitivity to angiotensin II.
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APPENDIX
PROGRAMS USED IN THE ANALYSIS OF RADIOLIGAND BINDING DATA
The Fortran programs below are given in standard format except that
comments are preceded by the "\" character and may occur on statement
lines. Each program becomes a subroutine to the main regression program
(BMDP PAR) defining the function under study. The programs and their
applications are described in detail in Chapter 3.
A. 1 General analysis of radioligand binding data
CALL MRD(P,F,X(1),X(2),X(3),X(4),X(7),X(8),X(9),X(10),X(11))
RETURN
END
SUBROUTINE MRD(P,F,CLASS,EXN,TYPE,HINIT,PROT,TINC,TDSS,FTR,FRR)
\
\Values of affinity (estimated for high & low affinity sites)
\ are common to all data
\Values of receptor density (for high & low affinity sites)
\ are common to all data in CLASS n 
\
\Input variables:
\HINIT Initial tracer concentration (units of IE-12 M)
\PROT Membrane protein concentration (units of mg/1)
\TINC, TDSS Association/dissociation time (units of s)
\FTR, FRR Fraction of tracer remaining/faction of receptors remaining
\ at end of association reaction
\EXN Used in receptor assay
\TYPE Modifies function
\
IMPLICIT REAL*8(A-H,0-Z)
DIMENSION Y(5),W(5,23),P(40)
EXTERNAL FCN
COMMON/PARAM/DKFl,DKF2,DKR1,DKR2,DKDH,DKDR
NCLASSCLASS+0.05D0
DKFl=10.0D0**P(1) \Forward &
DKR1=10.0D0**P(2) \ reverse rate constants, high affinity site
DKF2=10.0D0**P(3) \Forward &
DKR2=10.0D0**P(4) \ reverse rate constants, low affinity site
DKDH=-DLOG(FTR)/TINC \Rate constant, tracer decay
DKDR=-DLOG(FRR)/TINC \Rate constant, receptor decay
NTYPE=TYPE+0.05D0 
\Specify initial conditions for numerical integration 
Y(1)=HINIT \[Tracer]
Y(2)=P(NCLASS*2+3)*PROT \[Receptor (high affinity)]
Y(3)=P(NCLASS*2+4)*PROT \[Receptor (low affinity)]
Y(4)=0.0D0 \[Bound (high affinity)]
Y(5)=0.0D0 \[Bound (low affinity)]
XINIT=0.0D0
XEND=TINC
N=5
TOL=l.OD-3 
IFAIL=0
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\Call NAG routine for numerical integration
CALL D02EAF(XINIT,XEND,N,Y,TOL,FCN,W,23,IFAIL)
GOTO(10,20,30,40,50),NTYPE
\
10 CONTINUE
\Binding as a function of initial ligand concentration 
F=Y(4)+Y(5)
\F is predicted value of dependent variable returned to main program 
RETURN 
20 CONTINUE 
\Dissociation of receptor-bound ligand
F=Y(4)*DEXP(-DKRl*TDSS)+Y(5)*DEXP(-DKR2*TDSS)
RETURN
\Other values of NTYPE reserved for future expansion 
30 RETURN 
40 RETURN 
50 RETURN 
END
\Specify differential equations describing the reaction 
SUBROUTINE FCN(T,Y,F)
IMPLICIT REAL*8(A-H,0-Z)
DIMENSION Y(5),F(5)
COMMON/PARAM/DKFl,DKF2,DKRl,DKR2,DKDH,DKDR
F(1)=-DKFl*Y(1)*Y(2)-DKF2*Y(1)*Y(3)+DKR1*Y(4)+DKR2*Y(5)-DKDH*Y(1) 
F(2)=-DKFl*Y(1)*Y(2)+DKRl*Y(4)-DKDR*Y(2)
F(3)=-DKF2*Y(1)*Y(3)+DKR2*Y(5)
F(4)=DKF1*Y(1)*Y(2)-DKRl*Y(4)
F(5)=DKF2*Y(1)*Y(3)-DKR2*Y(5)
The corresponding BMDP control statements would be:
/PROBLEM TITLE IS 'RECEPTOR BINDING: 2 CLASSES OF SITES'.
/INPUT VARIABLES ARE 11.
FORMAT IS F3.0,F2.0,F2.0,F9.2,F9.4,F7.2,F6.1,F5.0,F6.0,2F6.3.
UNIT IS 8.
/VARIABLE NAMES ARE CLASS,EXN,TYPE,HINIT,BND,WGT,PROT,TINC,TDSS,FTR,FRR. 
/REGRESS DEPENDENT IS BND.
ITER=30.
PARAMETERS ARE 8.
WEIGHT=WGT.
/PARAMETER INITIAL ARE -6.000D0,-4.000D0,-7.000D0,-3.000D0,
0.100D0,0.010D0,0.100D0,0.010D0.
/NAMES ARE KFH,KRH,KFL,KRL,RHl,RLl,RH2/RL2.
/PLOT VAR=HINIT.
/END
KFH, KRH are the forward and reverse rate constants (high affinity sites)
KFL, KRL are the forward and reverse rate constants (low affinity sites)
RHn, RLn are the concentrations of high- and low-affinity binding sites
respectively for the data in CLASS n (n=l,2,3...)
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A.2 The receptor assay
CALL ASSAY(P,F,X(1),X(2),X(3),X(4),X(7),X(8),X(9),X(10),X(11))
RETURN
END
SUBROUTINE ASSAY(P,F,CLASS,EXN,TYPE,HINIT,PROT,TINC,TDSS,FTR,FRR)
\
\Values of affinity and receptor density are estimated for 
\ the high affinity site only
\Low affinity component of binding is assumed proportional to 
\ HINIT and the coefficient of proportionality estimated for 
\ each experiment (each value of EXN)
\Input variables: CLASS,EXN,TYPE,HINIT,PROT,TINC,TDSS,FTR,FRR 
\
IMPLICIT REAL*8(A-H,0-Z)
DIMENSION Y(3),W(3,23),P(40)
EXTERNAL FCN
COMMON/PARAM/DKFl,DKRl,DKDH,DKDR 
DKF1=10.0D0**P(1) \Forward &
DKR1=10.0D0**P(2) \ reverse rate constants, high affinity site
DKDH=-DU3G(FTR)/TINC \Rate constant, tracer decay
DKDR=-DLOG(FRR)/TINC \Rate constant, receptor decay
NXP=EXN+0.05D0
NTYPE=TYPE+0.05D0
DKR2=10**P(4) \Reverse rate constant, low affinity site
XLIN=P(NXP+4)*HINIT*PROT \Low affinity component of binding
\Specify initial conditions for numerical integration 
Y(1)=HINIT \[Tracer]
Y(2)=P(3)*PROT \[Receptor]
Y(3)=0.0D0 \[Bound tracer]
XINIT=0.0D0
XEND=TINC
N=3
TOL=l.OD-3 
IFAIL=0
\Call NAG routine for numerical integration
CALL D02EAF(XINIT,XEND,N,Y,TOL,FCN,W,23,IFAIL)
GOTO(10,20,30,40,50),NTYPE
\
10 CONTINUE
\Binding as a function of initial ligand concentration 
F=Y(3)+XLIN 
RETURN 
20 CONTINUE 
\Dissociation of receptor-bound ligand
F=Y(3)*DEXP(-DKR1*TDSS)+XLIN*DEXP(-DKR2*TDSS)
RETURN
\Other values of NTYPE reserved for future expansion 
30 RETURN 
40 RETURN 
50 RETURN 
END
\Specify differential equations describing the reaction 
SUBROUTINE FCN(T,Y,F)
IMPLICIT REAL*8(A-H,0-Z)
DIMENSION Y(3),F(3)
COMMON/PARAM/DKFl,DKRl,DKDH,DKDR 
F(1)=-DKFl*Y(1)*Y(2)+DKRl*Y(3)-DKDH*Y(1)
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F(2)=-DKFl*Y(1) *Y(2)+DKRl*Y(3)-DKDR*Y(2) 
F.( 3) =DKF1*Y (1) *Y (2) -DKRl*Y (3)
The corresponding BMDP control statements would be:
/PROBLEM TITLE IS 'ROUTINE RECEPTOR ASSAY'.
/INPUT VARIABLES ARE 11.
FORMAT IS F3.0, F2.0, F2.0, F9.2, F9.4, F7.2, F6.1, F5.0, F6.0,2F6.3.
UNIT IS 8.
/VARIABLE NAMES ARE CLASS,EXN,TYPE,HINIT,BND,WGT,PROT,TINC,TDSS,FTR,FRR. 
/REGRESS DEPENDENT IS BND.
ITER=30.
PARAMETERS ARE 7.
WEIGHT=WGT.
/PARAMETER INITIAL ARE -6.000D0,-4.000D0,0.100D0,-2.699D0,
1.00D-7,1.00D-7,1.00D-7.
/NAMES ARE KF,KR,RODP,KRL,LlDHDP,L2DHDP,L3DHDP.
/PLOT VAR=HINIT.
/END
KF, KR are the forward and reverse rate constants (high affinity site) 
RODP is the concentration of binding sites per unit protein 
KRL is the reverse rate constant for the low affinity site 
LnDHDP is the linear low affinity component of binding (per unit protein 
concentration per unit tracer concentration) for the n th 
experiment contributing to the pooled data (n=l,2,3...)
An example of the output from this program is shown in Figure 3.1.
A. 3 Competitive binding experiments
CALL DISP(P,F,X(1),X(3),X(4),X(5),X(6),X(7),X(8),X(9),X(10),X(11))
RETURN
END
SUBROUTINE DISP(P,F,CRV,CTL,DKT,CCL,DKC,TME,PROT,DKM,DX,DKR)
\
\Input variables are:
\CRV Curve number (identifies each competing ligand)
\CTL Concentration of tracer (units of IE-12 M)
\DKT Rate constant for tracer decay
\CCL Concentration of competing ligand (log [units of IE-12 M])
\DKC Rate constant for competing ligand decay
\TME Incubation time (min)
\PROT Membrane protein concentration (mg/1)
\DKR Rate constant receptor decay
\DKM Rate constant for decay of active metabolite of competing ligand
\DX Identifies metabolite as one of the other conpeting ligands 
\Assumed: competing ligand -> active metabolite -> inactive metabolite 
\
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IMPLICIT REAL*8(A-H,0-Z)
DIMENSION Y(7),W(7,25),P(40)
EXTERNAL FCN
COMMON/PARAM/DKFT,DKRT,DKFC,DKRC,DKFM,DKRM,DKDT,DKDC,DKDM,DKDR 
NCRV=CRV+0.05D0 
INDEX=DX+0.05D0 
DKFT=10.0D0**P(2)
DKRT=10.0D0**P(3)
DKDT=DKT*1.OD-5 
DKFC=10.0D0**P(NCRV*2+2)
DKRC=10.0D0**P(NCRV*2+3)
DKDC=DKC*1.OD-5 
DKDR=DKR*1.OD-5 
IF(INDEX.GT.O)THEN 
DKFM=10.0D0**P(INDEX*2+2)
DKRM=10.0D0**P(INDEX*2+3)
DKDM=DKM*1.OD-5 
ELSE 
DKFM=0.0D0 
DKRM=0.0D0 
DKDM=0.0D0 
END IF
\Specify initial conditions for numerical integration
\Forward &
\ reverse rates, tracer 
\Tracer decay rate 
\Forward &
\ reverse rates, competing ligand 
\Competing ligand decay rate 
\Receptor decay rate
\Forward &
\ reverse rates, active metabolite 
\Metabolite decay rate
\Tracer concentration 
\Competing ligand concentration 
\Active metabolite concentration 
\Receptor concentration 
\Bound tracer 
\Bound competing ligand 
\Bound metabolite
Y(1)=CTL
Y(2)=10.0D0**CCL 
Y(3)=0.0D0 
Y(4)=P(l)*PROT 
Y(5)=0.0D0 
Y(6)=0.0D0 
Y(7)=0.0D0 
XINIT=0.0D0 
XEND=TME*60.0D0 
N=7
TOL=1.0D-3
IFAIL=0
\Call NAG routine for numerical integration
CALL D02EAF(XINIT,XEND,N,Y,TOL,FCN,W,25,IFAIL)
CONTINUE
F=Y(5)
RETURN
END
\Specify differential equations describing the reaction 
SUBROUTINE FCN(T,Y,F)
IMPLICIT REAL*8(A-H,0-Z)
DIMENSION Y(7),F(7)
COMMON/PARAM/DKFT,DKRT,DKFC,DKRC,DKFM,DKRM,DKDT,DKDC,DKDM,DKDR 
F(1)=-DKFT*Y(1)*Y(4)+DKRT*Y(5)-DKDT*Y(1)
F(2)=-DKFC*Y(2)*Y(4)+DKRC*Y(6)-DKDC*Y(2)
F(3)=DKDC*Y(2)-DKFM*Y(3)*Y(4)+DKRM*Y(7)-DKDM*Y(3)
F(4)=-DKFT*Y(1)*Y(4)+DKRT*Y(5)-DKFC*Y(2)*Y(4)+DKRC*Y(6)
+ -DKFM*Y(3)*Y(4)+DKRM*Y(7)-DKDR*Y(4)
F(5)=DKFT*Y(1)*Y(4)-DKRT*Y(5)
F(6)=DKFC*Y(2)*Y(4)-DKRC*Y(6)
F(7)=DKFM*Y(3)*Y(4)-DKRM*Y(7)
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The corresponding BMDP control statements would be:
/PROBLEM TITLE IS 'MULTIPLE DISPLACEMENT CURVES'.
/INPUT VARIABLES ARE 12.
FORMAT IS F3.0,F8.3,F7.2,F6.1,F6.3,F10.3,F6.3,F3.0,F6.1,F6.3,F2.0,F6.3. 
UNIT IS 8.
/VARIABLE NAMES ARE CRV,BND,WGT,CTL,DKT,CCL,DKC,TME,PROT,DKM,DX,DKR 
/REGRESS DEPENDENT IS BND.
ITER=30.
PARAMETERS ARE 7.
WEIGHT=WGT.
/PARAMETER INITIAL ARE 0.100D0,-6.000D0,-4.000D0,
-6.000D0,-4.000D0,
-6.000D0,-4.000D0.
/NAMES ARE R0DP,KFT,KRT,KFl,KRl,KF2,KR2.
/END
RODP is the concentration of binding sites per unit protein 
KFT, KRT are the forward and reverse rate constants for the tracer 
KFn, KRn are the forward and reverse rate constants for the n th 
competing ligand (n=l,2,3...)
